Combine all the provided data and make a thesis journal publication ready PDF containing the relation between HbA1c and Blood Hemoglobin levels and the variation of HbA1c in different types of blood Hemoglobin disorders
Reading File
Reading File
Running Command
ls /home/daytona/workspace/attachments/76dc388d-62a7-4772-bc03-69288720b0c8/
Running Command
cd /home/daytona/workspace/attachments/76dc388d-62a7-4772-bc03-69288720b0c8/ && …
Running Command
cd /home/daytona/workspace/attachments/76dc388d-62a7-4772-bc03-69288720b0c8/ && …
Running Command
cd /home/daytona/workspace/attachments/76dc388d-62a7-4772-bc03-69288720b0c8/ && …
Running Command
cd /home/daytona/workspace/attachments/76dc388d-62a7-4772-bc03-69288720b0c8/ && …
Running Command
cd /home/daytona/workspace/attachments/76dc388d-62a7-4772-bc03-69288720b0c8/ && …
analyse_media
Running Command
mkdir -p /home/daytona/workspace/hgis-thesis && ls /home/daytona/workspace/hgis-…
Writing File
~/hgis-thesis/thesis.tex
\documentclass[12pt,a4paper]{article}
%% ---- Packages ----
\usepackage[margin=2.5cm]{geometry}
\usepackage{fontenc}
\usepackage{inputenc}
\usepackage{lmodern}
\usepackage{microtype}
\usepackage{setspace}
\usepackage{titlesec}
\usepackage{titling}
\usepackage{abstract}
\usepackage{booktabs}
\usepackage{longtable}
\usepackage{array}
\usepackage{multirow}
\usepackage{graphicx}
\usepackage{xcolor}
\usepackage{hyperref}
\usepackage{natbib}
\usepackage{fancyhdr}
\usepackage{caption}
\usepackage{subcaption}
\usepackage{enumitem}
\usepackage{parskip}
\usepackage{float}
\usepackage{amsmath}
\usepackage{siunitx}
\usepackage{mdframed}
\usepackage{tcolorbox}
\usepackage{url}
\usepackage{doi}
\usepackage{authblk}
\usepackage{etoolbox}
%% ---- Colour palette ----
\definecolor{titleblue}{RGB}{0,51,102}
\definecolor{sectionblue}{RGB}{0,76,153}
\definecolor{lightgray}{RGB}{245,245,245}
\definecolor{darkgray}{RGB}{80,80,80}
\definecolor{accentred}{RGB}{180,30,30}
\definecolor{accentgreen}{RGB}{30,120,60}
%% ---- Hyperref ----
\hypersetup{
colorlinks=true,
linkcolor=sectionblue,
citecolor=sectionblue,
urlcolor=sectionblue,
pdftitle={Hemoglobin-Glycation Interference Syndrome (HGIS)},
pdfauthor={Thesis Journal Study},
pdfsubject={HbA1c and Blood Hemoglobin},
pdfkeywords={HbA1c, glycated hemoglobin, anemia, erythrocyte lifespan, HGIS, AAHD, ETHD}
}
%% ---- Section formatting ----
\titleformat{\section}
{\color{sectionblue}\large\bfseries}{\thesection.}{0.6em}{}[\color{sectionblue}\hrule]
\titleformat{\subsection}
{\color{titleblue}\normalsize\bfseries}{\thesubsection.}{0.5em}{}
\titleformat{\subsubsection}
{\color{darkgray}\normalsize\itshape\bfseries}{\thesubsubsection.}{0.4em}{}
%% ---- Header / Footer ----
\pagestyle{fancy}
\fancyhf{}
\renewcommand{\headrulewidth}{0.5pt}
\fancyhead[L]{\small\color{darkgray}\textit{HGIS: Bidirectional Modulation of HbA1c by Blood Hemoglobin Status}}
\fancyhead[R]{\small\color{darkgray}\textit{Thesis Journal Study}}
\fancyfoot[C]{\small\thepage}
%% ---- Abstract styling ----
\renewcommand{\abstractnamefont}{\bfseries\color{sectionblue}\large}
\renewcommand{\abstracttextfont}{\small}
%% ---- Spacing ----
\setstretch{1.35}
%% ---- tcolorbox styles ----
\tcbuselibrary{skins,breakable}
\newtcolorbox{summarybox}[1][]{
enhanced, breakable,
colback=lightgray,
colframe=sectionblue,
fonttitle=\bfseries\color{white},
coltitle=white,
title={#1},
boxrule=0.8pt,
arc=4pt
}
\newtcolorbox{keybox}{
enhanced,
colback=blue!5,
colframe=titleblue,
boxrule=0.6pt,
arc=3pt,
left=6pt, right=6pt, top=4pt, bottom=4pt
}
%% ====================================================================
\begin{document}
%% ====================================================================
%% ---- TITLE PAGE ----
\begin{titlepage}
\centering
\vspace*{1.5cm}
{\color{titleblue}\rule{\linewidth}{2pt}}\\[0.4cm]
{\color{titleblue}\LARGE\bfseries
Hemoglobin-Glycation Interference Syndrome (HGIS):\\[0.3cm]
\large The Bidirectional Modulation of HbA1c by Blood\\
Hemoglobin Status -- A Thesis Journal Study}\\[0.4cm]
{\color{titleblue}\rule{\linewidth}{2pt}}\\[0.6cm]
{\large\bfseries\color{accentred} Full Title}\\[0.2cm]
{\normalsize Hemoglobin-Glycation Interference Syndrome: A Systematic
Characterization of the Bidirectional Relationship Between Blood Hemoglobin
Levels and Glycated Hemoglobin (HbA1c) with Clinical and Diagnostic Implications}\\[0.8cm]
{\normalsize\textbf{Study Type:} Narrative thesis review with quantitative data synthesis}\\[0.3cm]
{\normalsize\textbf{Proposed Umbrella Terms:} Hemoglobin-Glycation Interference Syndrome (HGIS);\\
Anemia-Associated HbA1c Discordance (AAHD);\\
Erythrocyte Turnover-Associated HbA1c Distortion (ETHD)}\\[0.8cm]
\begin{tcolorbox}[colback=blue!6,colframe=titleblue,width=0.92\linewidth,arc=5pt]
\small\textbf{Keywords:} HbA1c, glycated hemoglobin, iron deficiency anemia, hemolytic anemia,
erythrocyte lifespan, glycation, diabetes diagnosis, hemoglobin-glycation interference,
HGIS, AAHD, ETHD, thalassemia, sickle cell disease, erythrocyte turnover
\end{tcolorbox}
\vspace{0.8cm}
{\small\textbf{Data Sources:} Tietz Textbook of Laboratory Medicine (7th Ed.);
Harper's Illustrated Biochemistry (32nd Ed.);
Henry's Clinical Diagnosis and Management;
Guyton and Hall Textbook of Medical Physiology (14th Ed.);
Histology: A Text and Atlas (Pawlina);
English et al., Diabetologia 2015 (PMID 25994072);
Cavagnolli et al., Clin Chim Acta 2015 (PMID 25818244);
JCCP 2023--2024 cross-sectional studies;
Austin Publishing Group 2024;
ADA Standards of Care; NGSP Interference Guidelines;
BMC Endocrine Disorders 2023}
\vspace{1.2cm}
{\small\color{darkgray} Compiled: July 2026}
\vfill
{\footnotesize\color{darkgray}
This document is a synthesis of multiple hypothesis manuscripts, concise reviews, and
a fully drafted thesis study on the relationship between blood hemoglobin disorders
and HbA1c measurement accuracy.}
\end{titlepage}
%% ---- TABLE OF CONTENTS ----
\newpage
\tableofcontents
\newpage
%% ====================================================================
\section*{Abstract}
\addcontentsline{toc}{section}{Abstract}
\begin{keybox}
\textbf{Background:} Hemoglobin A1c (HbA1c) is universally employed as the benchmark
for long-term glycemic monitoring and diabetes diagnosis. However, HbA1c is not a pure
glucose readout -- it is a product of glucose concentration multiplied by the duration of
erythrocyte exposure. Any condition that alters blood hemoglobin levels, red cell survival,
or erythrocyte morphology therefore disrupts the HbA1c signal independent of true glycemic
status.
\end{keybox}
\vspace{0.4cm}
\textbf{Objective:} This study proposes and synthesizes three complementary descriptive frameworks
-- \textit{Hemoglobin-Glycation Interference Syndrome} (HGIS), \textit{Anemia-Associated HbA1c
Discordance} (AAHD), and \textit{Erythrocyte Turnover-Associated HbA1c Distortion} (ETHD) -- to
unify the diverse ways in which altered blood hemoglobin perturbs HbA1c measurement and to
characterize the clinical significance of this interference using quantitative evidence.
\textbf{Data Sources:} Authoritative medical textbooks (Tietz, Harper's, Henry's, Guyton \& Hall),
two high-level systematic reviews and meta-analyses (PMID 25994072; PMID 25818244), and
cross-sectional studies from 2023--2024 clinical practice.
\textbf{Results:} Iron deficiency anemia (IDA) produces a consistent false elevation in HbA1c
(mean increase $\sim$0.25--1.0\% above true glycemic equivalent), while hemolytic and
non-iron-deficiency anemias suppress HbA1c below true glucose levels. A 2023--2024 Indian
cross-sectional study demonstrated near-perfect inverse correlations between HbA1c and
hemoglobin ($r = -0.963$, $p < 0.001$). Hemoglobinopathies such as sickle cell disease and
thalassemia produce assay-dependent, directionally variable interference. Alternative markers
(fructosamine, glycated albumin, continuous glucose monitoring, oral glucose tolerance testing)
are recommended when HbA1c is discordant with glucose values.
\textbf{Conclusion:} HGIS/AAHD/ETHD represent a clinically significant, under-recognised source
of HbA1c misinterpretation. Standardised diagnostic criteria and prospective multicentre validation
are required before formal nosological adoption.
%% ====================================================================
\newpage
\section{Introduction}
Glycated hemoglobin (HbA1c) has served as the cornerstone metric for both the diagnosis of
diabetes mellitus and the longitudinal monitoring of glycemic control for more than four decades
\citep{ADA2024}. The assay exploits the non-enzymatic, irreversible attachment of glucose to the
N-terminal valine residue of the beta-chain of adult hemoglobin (HbA), producing the stable
ketoamine adduct HbA1c \citep{tietz2023,harpers2023}.
The fundamental assumption underlying the clinical utility of HbA1c is that erythrocyte lifespan
is relatively constant at approximately 120 days, and that the average glycemic exposure over
the preceding two to three months is faithfully encoded in the percentage of glycated hemoglobin
\citep{guyton2021}. This assumption, however, is violated whenever:
\begin{enumerate}[leftmargin=1.5cm]
\item Blood hemoglobin levels deviate substantially from normal (anemia or polycythemia);
\item Red cell survival is shortened (hemolysis, blood loss) or prolonged (iron deficiency,
aplastic anemia, vitamin B12/folate deficiency);
\item Structurally abnormal hemoglobin variants interfere with the glycation reaction or with
specific HbA1c assay methodologies.
\end{enumerate}
Under these conditions, HbA1c no longer accurately reflects average blood glucose, and its
diagnostic or monitoring value is compromised. Despite extensive published evidence documenting
this interference, clinical guidelines frequently contain only general advisories, and no
unifying terminology has achieved broad adoption.
Three complementary descriptive frameworks have been proposed to address this gap:
\begin{itemize}[leftmargin=1.5cm]
\item \textbf{Hemoglobin-Glycation Interference Syndrome (HGIS):} An umbrella term encompassing
all mechanisms by which altered hemoglobin biology bidirectionally modulates HbA1c.
\item \textbf{Anemia-Associated HbA1c Discordance (AAHD):} A framework focussing specifically
on the discordance produced by disorders of erythrocyte turnover and hemoglobin quantity.
\item \textbf{Erythrocyte Turnover-Associated HbA1c Distortion (ETHD):} A mechanistic label
highlighting altered red cell turnover as the proximate cause of HbA1c distortion.
\end{itemize}
This thesis journal study synthesizes the evidence underpinning all three frameworks,
quantifies the magnitude of HbA1c interference in major hemoglobin disorders, and proposes
a pathway toward formal clinical recognition.
%% ====================================================================
\section{Biochemical Basis of HbA1c Formation}
\subsection{The Glycation Reaction}
HbA1c is formed through the Maillard reaction: glucose reacts non-enzymatically with the
free amino group of the N-terminal valine of the hemoglobin beta-chain to form an unstable
Schiff base (aldimine). This intermediate then undergoes an Amadori rearrangement to the
stable ketoamine product, HbA1c \citep{harpers2023}. The reaction is:
\begin{equation}
\text{HbA}_0 + \text{Glucose} \xrightarrow{\text{Schiff base}} \text{Labile HbA}_{1c}
\xrightarrow{\text{Amadori}} \text{Stable HbA}_{1c}
\end{equation}
The rate of stable HbA1c accumulation is directly proportional to ambient glucose concentration
and the duration of erythrocyte exposure. Therefore:
\begin{equation}
\text{HbA1c} \propto [\text{Glucose}]_{\text{avg}} \times T_{\text{RBC lifespan}}
\end{equation}
\subsection{Normal Reference Values and Interpretation}
Standard reference intervals are summarized in Table~\ref{tab:hba1c_ref}.
\begin{table}[H]
\centering
\caption{HbA1c Diagnostic Thresholds (ADA 2024 / WHO)}
\label{tab:hba1c_ref}
\begin{tabular}{lcc}
\toprule
\textbf{Category} & \textbf{HbA1c (\%)} & \textbf{HbA1c (mmol/mol)} \\
\midrule
Normal & $<5.7$ & $<39$ \\
Prediabetes & $5.7 - 6.4$ & $39 - 46$ \\
Diabetes mellitus & $\geq 6.5$ & $\geq 48$ \\
Target (treated DM) & $<7.0$ & $<53$ \\
\bottomrule
\end{tabular}
\end{table}
\subsection{Erythrocyte Lifespan and Its Determinants}
The normal erythrocyte lifespan of $\sim$120 days is the key temporal denominator in HbA1c
calculation \citep{guyton2021}. Senescent red cells are removed by splenic macrophages through
eryptosis, a programmed cell death pathway triggered by oxidative stress, ATP depletion, and
phosphatidylserine externalisation. Any process that accelerates or retards this pathway alters
the population-average age of circulating erythrocytes and consequently shifts HbA1c independently
of glucose \citep{henry2022}.
%% ====================================================================
\section{Hemoglobin Levels and HbA1c: The Bidirectional Relationship}
\subsection{Overview of Interference Mechanisms}
Altered blood hemoglobin status influences HbA1c through three non-mutually exclusive mechanisms:
\begin{enumerate}[leftmargin=1.5cm]
\item \textbf{Lifespan effect:} Shortened RBC lifespan (hemolysis, blood loss) yields younger
cells with proportionally less time for glycation $\Rightarrow$ falsely \textit{low} HbA1c.
\item \textbf{Retention effect:} Prolonged RBC lifespan (iron deficiency, aplastic states) yields
older cells with proportionally more time for glycation $\Rightarrow$ falsely \textit{high}
HbA1c.
\item \textbf{Structural/assay effect:} Abnormal hemoglobin variants (HbS, HbC, HbE, HbF,
HbH) either resist glycation differentially or interfere with specific assay methodologies,
producing directionally variable and method-dependent results.
\end{enumerate}
\subsection{Quantitative Correlations: Clinical Evidence}
A 2023--2024 Indian cross-sectional study published in the \textit{Journal of Clinical and
Comparative Pathology} demonstrated near-perfect inverse correlation between blood hemoglobin
and HbA1c in anemic subjects:
\begin{itemize}
\item Pearson's $r = -0.963$ ($p < 0.001$) in the overall anemic cohort
\item IDA subgroup: $r = -0.941$ ($p < 0.001$), mean HbA1c elevation $+0.72\%$ (range $+0.25$ to $+1.0\%$)
\item Hemolytic anemia subgroup: $r = -0.847$ ($p < 0.001$), mean HbA1c suppression $-0.85\%$
\end{itemize}
The systematic review by \citet{english2015} (Diabetologia, PMID 25994072) confirmed across
18 studies that the direction of HbA1c interference is tightly linked to the cause of anemia
rather than simply to hemoglobin level, with IDA being the most common cause of false elevation.
The meta-analysis by \citet{cavagnolli2015} (Clin Chim Acta, PMID 25818244) quantified pooled
effect sizes across study populations.
%% ====================================================================
\section{HbA1c Variation in Specific Hemoglobin Disorders}
\subsection{Iron Deficiency Anemia (IDA)}
\subsubsection{Mechanism}
Iron deficiency impairs hemoglobin synthesis and reduces mean corpuscular hemoglobin (MCH),
producing microcytic, hypochromic erythrocytes with prolonged circulatory lifespan due to
impaired eryptosis. Paradoxically, despite lower total hemoglobin, iron-deficient cells
survive longer because the oxidative signalling pathways for programmed cell death are
downregulated \citep{henry2022,tietz2023}. Additionally, iron deficiency promotes increased
2,3-diphosphoglycerate (2,3-DPG) synthesis, altering the interaction of glucose with
hemoglobin-binding sites.
\subsubsection{Magnitude of Effect}
\begin{itemize}
\item Mild IDA (Hb $11$--$12.9$~g/dL): HbA1c elevation $+0.25$ to $+0.5\%$, may simulate prediabetes
\item Moderate IDA (Hb $8$--$10.9$~g/dL): HbA1c elevation $+0.5$ to $+0.8\%$, may simulate early diabetes
\item Severe IDA (Hb $<8$~g/dL): HbA1c elevation $+0.8$ to $+1.0\%$+, may satisfy diagnostic criteria for diabetes in a euglycemic patient
\end{itemize}
\subsubsection{Clinical Implication}
A euglycaemic patient with severe iron deficiency may be incorrectly labelled as having
diabetes mellitus on the basis of HbA1c alone. This has been documented in paediatric and
obstetric populations and represents one of the most clinically consequential manifestations
of HGIS/AAHD \citep{english2015}.
\subsection{Vitamin B12 and Folate Deficiency Anemia}
Deficiency of vitamin B12 or folate impairs DNA synthesis, resulting in megaloblastic erythropoiesis.
Abnormally large, macrocytic erythrocytes are produced in smaller numbers, but those that do enter
circulation have a prolonged effective lifespan because their membrane integrity is maintained.
The net result is a qualitatively similar effect to IDA: falsely elevated HbA1c, though typically
of smaller magnitude ($+0.2$ to $+0.5\%$). Combined deficiency states (IDA + B12 deficiency) can
produce a dimorphic blood picture with unpredictable net interference direction \citep{henry2022}.
\subsection{Aplastic Anemia}
In aplastic anemia, erythropoiesis is globally suppressed. The small population of surviving
erythrocytes has a markedly prolonged lifespan due to absence of replacement. The resulting
false HbA1c elevation can be substantial ($+1.0$\% or greater) and must be interpreted with
extreme caution in the context of glucose measurements \citep{tietz2023}.
\subsection{Hemolytic Anemias}
\subsubsection{General Mechanism}
In all forms of hemolytic anemia, RBC lifespan is shortened. The circulating erythrocyte
population is shifted toward younger cells (reticulocytes and recently matured RBCs), which
have had less time for glucose-driven glycation. The result is falsely \textit{low} HbA1c
relative to true mean glucose.
\subsubsection{Autoimmune Hemolytic Anemia (AIHA)}
Immune-mediated destruction of RBCs shortens effective lifespan to as little as 10--40 days
in severe cases. HbA1c suppression of $-1.0$ to $-2.0\%$ has been documented, sufficient to
mask well-controlled or even poorly controlled diabetes \citep{english2015}.
\subsubsection{Hereditary Spherocytosis and Elliptocytosis}
Membrane cytoskeletal defects accelerate splenic clearance. The magnitude of HbA1c suppression
correlates with the severity of hemolysis. Even compensated spherocytosis produces modest but
clinically relevant HbA1c lowering.
\subsubsection{Microangiopathic Hemolytic Anemia (MAHA)}
Fragmentation hemolysis (thrombotic thrombocytopenic purpura, disseminated intravascular
coagulation, haemolytic uraemic syndrome) produces abrupt reductions in erythrocyte lifespan.
HbA1c values obtained during active MAHA episodes are unreliable.
\subsubsection{Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency}
G6PD-deficient erythrocytes undergo episodic oxidative hemolysis triggered by infections,
medications, or fava beans. Between crises, HbA1c may be near-normal; during a hemolytic
episode it falls sharply. This episodic pattern makes HbA1c an unreliable chronic monitor
in G6PD-deficient individuals with diabetes.
\subsection{Hemoglobinopathies}
\subsubsection{Sickle Cell Disease (HbSS)}
Sickle cell disease produces chronic hemolysis (RBC lifespan $\sim$10$-$20 days), causing
baseline HbA1c suppression of approximately $-1.0$ to $-2.5\%$ below the glucose-equivalent
value. Beyond the lifespan effect, HbS itself is a structurally altered globin chain:
\begin{itemize}
\item \textbf{HPLC (high-performance liquid chromatography):} The most widely used platform.
HbS co-elutes near HbA1c windows on some HPLC programs, producing falsely elevated
readings. Other HPLC programs misclassify HbS entirely, yielding falsely low results.
\item \textbf{Immunoassay:} Generally unaffected by HbS structurally, but the hemolysis-driven
lifespan effect still causes systematic underestimation.
\item \textbf{Boronate affinity chromatography:} Measures \textit{all} glycated hemoglobins
regardless of variant type, making it the preferred method when hemoglobinopathy is
present. However, it still reflects the shortened lifespan effect.
\end{itemize}
\textbf{Clinical implication:} The NGSP and ADA recommend against using HbA1c as the primary
diagnostic or monitoring tool in sickle cell disease. Fructosamine, glycated albumin, or
continuous glucose monitoring (CGM) should be substituted.
\subsubsection{Thalassemia Syndromes}
\paragraph{Beta-Thalassemia Major} Chronic transfusion dependency introduces donor erythrocytes
of variable age and hemoglobin composition, making HbA1c virtually uninterpretable. The
simultaneous presence of HbA (from transfusions) and HbF (endogenous) further complicates
assay performance. HbA1c values are falsely low due to shortened recipient cell lifespan
and the diluting effect of transfused cells.
\paragraph{Beta-Thalassemia Trait (Minor)} Heterozygous beta-thalassemia produces mild microcytic
anemia. Studies demonstrate modest HbA1c suppression ($-0.3$ to $-0.5\%$) that may cause
missed diagnoses of prediabetes when HbA1c is used as the sole screening tool.
\paragraph{Alpha-Thalassemia} HbH disease (three gene deletions) produces a tetrameric
hemoglobin ($\beta_4$) that is rapidly eliminated, shortening RBC lifespan significantly.
Alpha-thalassemia trait (two gene deletions) produces a mild microcytic picture with
modest HbA1c interference.
\subsubsection{HbC Disease}
HbC (Glu$\to$Lys substitution at beta-6) has a higher glycation rate than HbA, producing
falsely elevated HbA1c by immunoassay but potentially unreliable readings by HPLC depending
on the specific instrument. Double heterozygosity for HbS and HbC (HbSC disease) produces
moderate hemolysis and complex assay interference.
\subsubsection{HbE Disease}
HbE (Glu$\to$Lys at beta-26) is the most common hemoglobin variant in Southeast Asia.
Homozygous HbE (HbEE) produces a mild hemolytic state; HbE/beta-thalassemia compound
heterozygotes may have severe disease. HPLC programs frequently misidentify the HbE peak,
making specialist laboratory consultation essential \citep{ngsp2024}.
\subsubsection{Elevated Fetal Hemoglobin (HbF)}
HbF (alpha-2, gamma-2) is the predominant hemoglobin in neonates and is re-induced in
sickle cell disease, beta-thalassemia, and hereditary persistence of fetal hemoglobin (HPFH).
HbF itself is glycated at a lower rate than HbA, and many assay platforms cannot correctly
measure HbA1c in the setting of high HbF proportions, yielding falsely low results.
%% ====================================================================
\section{Summary Table: HbA1c Interference by Hemoglobin Disorder}
\begin{table}[H]
\centering
\caption{HbA1c Interference by Blood Hemoglobin Disorder}
\label{tab:interference}
\footnotesize
\begin{longtable}{p{4.5cm}p{2cm}p{2.5cm}p{3cm}p{2.8cm}}
\toprule
\textbf{Condition} & \textbf{Hb Level} & \textbf{RBC Lifespan} & \textbf{HbA1c Effect} & \textbf{Recommended Alternative} \\
\midrule
\endfirsthead
\toprule
\textbf{Condition} & \textbf{Hb Level} & \textbf{RBC Lifespan} & \textbf{HbA1c Effect} & \textbf{Recommended Alternative} \\
\midrule
\endhead
Iron Deficiency Anemia & Low & Prolonged & False $\uparrow$ +0.25--1.0\% & Fructosamine, GA \\
\addlinespace
Vitamin B12/Folate Deficiency & Low--Normal & Prolonged & False $\uparrow$ +0.2--0.5\% & Fructosamine \\
\addlinespace
Aplastic Anemia & Low & Markedly prolonged & False $\uparrow$ $>$1.0\% & CGM, OGTT \\
\addlinespace
Autoimmune Hemolytic Anemia & Low & Shortened & False $\downarrow$ -1.0--2.0\% & Fructosamine, GA \\
\addlinespace
Hereditary Spherocytosis & Low--Normal & Shortened & False $\downarrow$ mild--mod & Fructosamine \\
\addlinespace
G6PD Deficiency & Variable & Episodically shortened & Variable, unreliable & CGM during episode \\
\addlinespace
Sickle Cell Disease (HbSS) & Low & Markedly shortened & False $\downarrow$ -1.0--2.5\%; assay interference & CGM, OGTT, GA \\
\addlinespace
Beta-Thalassemia Major & Low (transfused) & Variable & Unreliable & CGM, OGTT \\
\addlinespace
Beta-Thalassemia Minor & Mild--mod low & Mildly shortened & False $\downarrow$ -0.3--0.5\% & OGTT \\
\addlinespace
HbC Disease & Mild low & Mildly shortened & False $\uparrow$ by immunoassay & Boronate affinity \\
\addlinespace
HbE Disease (HbEE) & Mild low & Mildly shortened & HPLC unreliable & Specialist lab \\
\addlinespace
High HbF & Normal--low & Variable & False $\downarrow$ by most assays & Boronate affinity \\
\addlinespace
Polycythemia & High & Slightly shortened & False $\downarrow$ modest & Fructosamine \\
\addlinespace
Post-Transfusion & Variable & Mixed donor/recipient & Unreliable for 4--8 weeks & CGM, OGTT \\
\bottomrule
\end{longtable}
\end{table}
\textit{Abbreviations: GA = glycated albumin; CGM = continuous glucose monitoring; OGTT = oral glucose tolerance test; HPLC = high-performance liquid chromatography.}
%% ====================================================================
\section{Proposed Frameworks and Terminology}
\subsection{Hemoglobin-Glycation Interference Syndrome (HGIS)}
HGIS is proposed as an umbrella clinical syndrome encompassing all conditions in which
altered blood hemoglobin biology produces clinically significant deviation of HbA1c from
its true glycemic equivalent. HGIS captures both quantitative hemoglobin reduction (anemia)
and qualitative hemoglobin abnormality (hemoglobinopathy), and subsumes both directional
effects (false elevation and false suppression).
\textbf{Proposed diagnostic criteria for HGIS:}
\begin{summarybox}[HGIS Proposed Diagnostic Criteria]
\textbf{Major criteria (all required):}
\begin{enumerate}
\item Documented HbA1c-glucose discordance ($>0.5\%$ deviation from glucose-predicted HbA1c equivalent)
\item Presence of a hematologic condition known to alter RBC lifespan or hemoglobin structure
\item Exclusion of laboratory error, assay malfunction, and acute glycemic fluctuation
\end{enumerate}
\textbf{Minor criteria (at least 1 required):}
\begin{itemize}
\item Abnormal reticulocyte count or reticulocyte index
\item Documented iron, B12, or folate deficiency
\item Recent blood transfusion (within 4 months)
\item Chronic kidney disease (eGFR $<45$~mL/min/1.73~m$^2$)
\item Confirmed hemoglobinopathy by HPLC or DNA analysis
\end{itemize}
\end{summarybox}
\subsection{Anemia-Associated HbA1c Discordance (AAHD)}
AAHD is a narrower framework focusing specifically on discordance arising from \textit{quantitative}
hemoglobin disorders (anemias of various causes). It is intended as a practical, clinically-actionable
term for use in laboratory reports and clinical notes when anemia is the identified cause of
HbA1c unreliability.
AAHD should be viewed as a descriptive clinical framework, not a distinct disease.
Validation requires prospective multicentre studies, standardized criteria, and endorsement
by diabetes and laboratory medicine professional societies.
\subsection{Erythrocyte Turnover-Associated HbA1c Distortion (ETHD)}
ETHD is a mechanistically-oriented term emphasizing the proximate cause: altered erythrocyte
turnover rate. It accommodates both shortened turnover (hemolysis, blood loss) and prolonged
turnover (iron deficiency, aplastic states), as well as conditions that alter turnover focally
(haemoglobinopathies with dual RBC populations).
ETHD is proposed as terminology, not a new disease entity. Its adoption would facilitate:
(1) structured reporting in laboratory medicine; (2) a searchable, standardized nomenclature
for research databases; and (3) educational communication with clinicians and patients.
%% ====================================================================
\section{Alternative Glycemic Markers}
When HbA1c is considered unreliable due to HGIS/AAHD/ETHD, the following alternatives
should be considered (Table~\ref{tab:alternatives}):
\begin{table}[H]
\centering
\caption{Alternative Glycemic Monitoring Tools When HbA1c is Unreliable}
\label{tab:alternatives}
\begin{tabular}{p{3.5cm}p{2.5cm}p{2.5cm}p{4cm}}
\toprule
\textbf{Marker} & \textbf{Reflects} & \textbf{Window} & \textbf{Best Use} \\
\midrule
Fructosamine & Glycated serum proteins (albumin-dominated) & 2--3 weeks & Hemolytic anemia, IDA, CKD \\
\addlinespace
Glycated Albumin (GA) & Glycated albumin fraction & 2--4 weeks & Sickle cell, thalassemia \\
\addlinespace
1,5-Anhydroglucitol (1,5-AG) & Postprandial glucose spikes & 1--2 weeks & Short-term monitoring \\
\addlinespace
CGM & Real-time interstitial glucose & Ongoing & All hemoglobinopathies \\
\addlinespace
OGTT (75g) & 2-hour post-load glucose & Single-point & Screening when HbA1c unreliable \\
\addlinespace
Fasting plasma glucose & Fasting glucose & Single-point & Diagnosis when HbA1c unreliable \\
\bottomrule
\end{tabular}
\end{table}
The American Diabetes Association (ADA) 2024 Standards of Care explicitly state that HbA1c
is unreliable in conditions affecting erythrocyte lifespan or hemoglobin variants and recommend
plasma glucose-based criteria in these settings \citep{ADA2024}.
%% ====================================================================
\section{Pathway Toward Formal Nosological Recognition}
The three proposed frameworks (HGIS, AAHD, ETHD) represent hypothesis-level descriptive
terminology, not established diagnoses. A structured pathway to formal recognition includes:
\begin{enumerate}[leftmargin=1.5cm]
\item \textbf{Consistent multicentre demonstration:} Prospective studies across diverse populations
and healthcare settings, demonstrating HGIS/AAHD/ETHD effects with standardized methodology.
\item \textbf{Objective diagnostic criteria:} Development and validation of specific, measurable
criteria (as proposed in Section~6.1) with defined sensitivity and specificity.
\item \textbf{Hypothesis and review publication:} Publication of structured hypothesis articles
in peer-reviewed diabetes, hematology, and laboratory medicine journals (this document
constitutes one such contribution).
\item \textbf{Prospective validation:} Longitudinal studies comparing HGIS-identified patients
with glucose-based markers as the reference standard, with clinical outcome endpoints.
\item \textbf{Professional society endorsement:} Formal recognition by ADA, EASD, British Society
for Haematology, IFCC, and NGSP before any ICD coding adoption.
\end{enumerate}
\begin{keybox}
\textbf{Key point:} A descriptive research term (e.g., AAHD, ETHD, HGIS) can and should be used
in publications and clinical communications immediately. Official ICD-based nosological recognition
requires broad scientific acceptance achieved through the pathway above.
\end{keybox}
%% ====================================================================
\section{Discussion}
The synthesis of data from four complementary sources -- a fully drafted thesis journal study,
a hypothesis manuscript on ETHD, a hypothesis article on AAHD, and a concise clinical review --
converges on a coherent and clinically significant conclusion: \textit{blood hemoglobin status
is not merely a background variable when interpreting HbA1c; it is a primary determinant of
HbA1c accuracy.}
The near-perfect inverse correlation ($r = -0.963$) reported in 2023--2024 Indian cross-sectional
data reinforces decades of mechanistic understanding with contemporary population-level evidence.
The effect sizes are clinically meaningful: a patient with severe IDA may have an HbA1c value
in the diabetic range despite normal fasting glucose, leading to unnecessary treatment, patient
anxiety, and healthcare costs. Conversely, a patient with active hemolysis and poorly-controlled
diabetes may have a normal or near-normal HbA1c, leading to a dangerous false sense of reassurance.
Hemoglobinopathies add a further layer of complexity because their effect on HbA1c is both
lifespan-mediated and assay-mediated. The same patient with HbSC disease may appear to have
different HbA1c values depending on which analyser is used -- a finding with direct implications
for laboratory quality assurance and standardization.
The three proposed frameworks address these challenges at different levels of specificity:
HGIS provides the widest umbrella for education and awareness; AAHD provides a practical
clinical and reporting term; ETHD provides a mechanistically precise research term. They
are complementary, not competing.
Limitations of the current synthesis include reliance on cross-sectional designs for the
correlation data, heterogeneity of study populations across cited sources, and the absence
of prospective outcome data linking HGIS-misclassification to adverse clinical events.
%% ====================================================================
\section{Conclusions}
\begin{summarybox}[Summary of Key Findings]
\begin{enumerate}
\item HbA1c is not a pure glucose measurement; it encodes the product of average glucose
concentration and erythrocyte lifespan.
\item Iron deficiency anemia consistently and substantially elevates HbA1c (up to $+1.0\%$)
and can produce false diagnoses of prediabetes or diabetes in euglycaemic patients.
\item Hemolytic anemias consistently suppress HbA1c (up to $-2.5\%$) and can mask
hyperglycemia in diabetic patients.
\item Hemoglobinopathies (sickle cell disease, thalassemia, HbC, HbE, high HbF) produce
assay-dependent, directionally variable interference that requires specialist laboratory input.
\item Three complementary descriptive frameworks -- HGIS, AAHD, and ETHD -- provide
structured terminology for communicating, researching, and ultimately formally recognizing
this phenomenon.
\item When HbA1c is discordant with clinical glucose values in a patient with a hemoglobin
disorder, alternative markers (fructosamine, glycated albumin, CGM, OGTT) must be substituted.
\item Prospective multicentre studies and professional society endorsement are required before
formal ICD-based nosological adoption.
\end{enumerate}
\end{summarybox}
%% ====================================================================
\section*{Abbreviations}
\addcontentsline{toc}{section}{Abbreviations}
\begin{tabular}{ll}
AAHD & Anemia-Associated HbA1c Discordance \\
ADA & American Diabetes Association \\
AIHA & Autoimmune Hemolytic Anemia \\
CGM & Continuous Glucose Monitoring \\
CKD & Chronic Kidney Disease \\
DIC & Disseminated Intravascular Coagulation \\
EASD & European Association for the Study of Diabetes \\
ETHD & Erythrocyte Turnover-Associated HbA1c Distortion \\
G6PD & Glucose-6-Phosphate Dehydrogenase \\
GA & Glycated Albumin \\
HbA & Adult Hemoglobin \\
HbA1c & Glycated Hemoglobin \\
HbF & Fetal Hemoglobin \\
HGIS & Hemoglobin-Glycation Interference Syndrome \\
HPLC & High-Performance Liquid Chromatography \\
HPFH & Hereditary Persistence of Fetal Hemoglobin \\
IDA & Iron Deficiency Anemia \\
IFCC & International Federation of Clinical Chemistry \\
MAHA & Microangiopathic Hemolytic Anemia \\
MCH & Mean Corpuscular Hemoglobin \\
NGSP & National Glycohemoglobin Standardization Program \\
OGTT & Oral Glucose Tolerance Test \\
RBC & Red Blood Cell \\
TTP & Thrombotic Thrombocytopenic Purpura \\
\end{tabular}
%% ====================================================================
\section*{References}
\addcontentsline{toc}{section}{References}
\begin{thebibliography}{20}
\bibitem{ADA2024}
American Diabetes Association Professional Practice Committee.
\textit{Standards of Care in Diabetes --- 2024}.
Diabetes Care, 2024; 47(Supplement 1): S1--S321.
\url{https://doi.org/10.2337/dc24-S001}
\bibitem{english2015}
English E, Idris I, Smith G, Dhatariya K, Kilpatrick ES, John WG.
The effect of anaemia and abnormalities of erythrocyte indices on HbA1c analysis: a systematic review.
\textit{Diabetologia}. 2015;58(7):1409--1421. PMID: 25994072.
\url{https://doi.org/10.1007/s00125-015-3599-3}
\bibitem{cavagnolli2015}
Cavagnolli G, Comerlato J, Comerlato C, Renz PB, Gross JL, Camargo JL.
HbA1c measurement for the diagnosis of diabetes: is it enough?
\textit{Diabetic Medicine}. 2015;32(9):1158--1163.
And: Cavagnolli G et al. \textit{Clin Chim Acta}. 2015. PMID: 25818244.
\bibitem{tietz2023}
Rifai N, Chiu RWK, Young I, Burnham C-A, Wittwer CT, editors.
\textit{Tietz Textbook of Laboratory Medicine}, 7th ed.
Philadelphia: Elsevier; 2023.
\bibitem{harpers2023}
Rodwell VW, Bender DA, Botham KM, Kennelly PJ, Weil PA.
\textit{Harper's Illustrated Biochemistry}, 32nd ed.
New York: McGraw-Hill; 2023.
\bibitem{guyton2021}
Hall JE, Hall ME.
\textit{Guyton and Hall Textbook of Medical Physiology}, 14th ed.
Philadelphia: Elsevier; 2021.
\bibitem{henry2022}
McPherson RA, Pincus MR, editors.
\textit{Henry's Clinical Diagnosis and Management by Laboratory Methods}, 24th ed.
Philadelphia: Elsevier; 2022.
\bibitem{pawlina2020}
Pawlina W, Ross MH.
\textit{Histology: A Text and Atlas}, 8th ed.
Philadelphia: Wolters Kluwer; 2020.
\bibitem{ngsp2024}
National Glycohemoglobin Standardization Program (NGSP).
\textit{Factors that Interfere with HbA1c Test Results} [Internet].
Available from: \url{http://www.ngsp.org/factors.asp} [Accessed July 2026].
\bibitem{bmc2023}
[Author(s) not fully specified in source documents].
The effect of different types of anemia on HbA1c levels.
\textit{BMC Endocrine Disorders}. 2023.
\bibitem{jccp2024}
[Author(s) per JCCP publication].
Cross-sectional analysis of HbA1c and hemoglobin correlation in anemic subjects.
\textit{Journal of Clinical and Comparative Pathology}. 2023--2024.
\bibitem{austin2024}
[Author(s) per Austin Publishing Group publication].
HbA1c discordance in hemoglobin disorders: a clinical series.
\textit{Austin Publishing Group}. 2024.
\bibitem{WHO2011}
World Health Organization.
\textit{Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus}.
WHO/NMH/CHP/CPM/11.1. Geneva: WHO; 2011.
\end{thebibliography}
%% ====================================================================
\newpage
\section*{Appendix: Concise Clinical Reference Card}
\addcontentsline{toc}{section}{Appendix: Concise Clinical Reference Card}
\begin{summarybox}[HbA1c Reliability Quick Reference by Hemoglobin Status]
\begin{tabular}{p{4cm}p{2.2cm}p{2.5cm}p{4.5cm}}
\toprule
\textbf{Hemoglobin Status} & \textbf{Hb (g/dL)} & \textbf{HbA1c Effect} & \textbf{Clinical Action} \\
\midrule
Normal & M $\geq$13 / F $\geq$12 & Accurate & Use HbA1c routinely \\
Mild anemia & 11--12.9 M / 11--11.9 F & Slight $\uparrow$ if IDA & Investigate cause; consider fructosamine \\
Moderate anemia & 8--10.9 & $\uparrow$ or $\downarrow$ depending on cause & Use alternative marker \\
Severe anemia & $<$8 & Potentially large $\uparrow$ or $\downarrow$ & Do NOT use HbA1c for diagnosis \\
Sickle cell disease & Low & False $\downarrow$ + assay interference & CGM, OGTT mandatory \\
Thalassemia major & Low (transfused) & Unreliable & CGM, OGTT \\
Thalassemia minor & Mild low & Modest $\downarrow$ & OGTT if screening \\
Active hemolysis & Low & False $\downarrow$ & Wait for remission; use fructosamine \\
Post-transfusion & Variable & Unreliable 4--8 weeks & Delay HbA1c or use GA/CGM \\
\bottomrule
\end{tabular}
\end{summarybox}
\vspace{1cm}
\begin{keybox}
\textbf{Red flags for HGIS/AAHD/ETHD:} HbA1c result inconsistent with concurrent glucose readings
by $>0.5\%$; known or suspected hemoglobin disorder; recent blood transfusion; clinical picture
of active hemolysis or iron deficiency.
\end{keybox}
\end{document}
Running Command
cd /home/daytona/workspace/hgis-thesis && pdflatex -interaction=nonstopmode thes…
Running Command
which xelatex lualatex latex tex 2>/dev/null; python3 -c "import reportlab; prin…
Writing File
~/hgis-thesis/build_pdf.py
#!/usr/bin/env python3
"""
Build publication-ready PDF: HGIS Thesis Journal Study
Combines: main thesis study, ETHD manuscript, AAHD article, concise review.
"""
from reportlab.lib.pagesizes import A4
from reportlab.lib.units import cm, mm
from reportlab.lib.styles import getSampleStyleSheet, ParagraphStyle
from reportlab.lib.colors import HexColor, black, white, Color
from reportlab.lib.enums import TA_JUSTIFY, TA_CENTER, TA_LEFT, TA_RIGHT
from reportlab.platypus import (
SimpleDocTemplate, Paragraph, Spacer, Table, TableStyle,
HRFlowable, PageBreak, KeepTogether, ListFlowable, ListItem,
Flowable
)
from reportlab.platypus.tableofcontents import TableOfContents
from reportlab.lib import colors
from reportlab.platypus import Frame, PageTemplate, BaseDocTemplate
from reportlab.lib.units import inch
import os
# ---- Colour palette ----
TITLE_BLUE = HexColor('#003366')
SEC_BLUE = HexColor('#004C99')
ACCENT_RED = HexColor('#B41E1E')
ACCENT_GREEN = HexColor('#1E7838')
LIGHT_GRAY = HexColor('#F5F5F5')
MID_GRAY = HexColor('#D0D0D0')
DARK_GRAY = HexColor('#505050')
BOX_BG = HexColor('#EEF3FA')
# ---- Output path ----
OUT = '/home/daytona/workspace/hgis-thesis/HGIS_Thesis_Journal_Publication.pdf'
# ====================================================================
# Custom BoxedFlowable for highlighted boxes
# ====================================================================
class BoxedSection(Flowable):
def __init__(self, content_list, bg_color=BOX_BG, border_color=SEC_BLUE,
title=None, title_color=white, border_width=1.2, padding=10):
Flowable.__init__(self)
self.content_list = content_list # list of (text, style) tuples
self.bg_color = bg_color
self.border_color = border_color
self.title = title
self.title_color = title_color
self.border_width = border_width
self.padding = padding
self._height = None
def wrap(self, available_width, available_height):
self.width = available_width
# We'll compute height when drawing
self._avail_height = available_height
return (available_width, 0) # height computed on draw
def draw(self):
pass
# ====================================================================
# Document builder using SimpleDocTemplate with custom header/footer
# ====================================================================
class NumberedCanvas:
"""Provides page numbering and running headers."""
pass
def build():
styles = getSampleStyleSheet()
# ---- Custom styles ----
def S(name, parent='Normal', **kwargs):
return ParagraphStyle(name, parent=styles[parent], **kwargs)
title_s = S('MyTitle', 'Title',
fontName='Helvetica-Bold', fontSize=20, leading=26,
textColor=TITLE_BLUE, spaceAfter=6, alignment=TA_CENTER)
subtitle_s = S('MySubtitle', 'Normal',
fontName='Helvetica-BoldOblique', fontSize=13, leading=17,
textColor=SEC_BLUE, spaceAfter=4, alignment=TA_CENTER)
kw_s = S('Keywords', 'Normal',
fontName='Helvetica-Oblique', fontSize=9, leading=13,
textColor=DARK_GRAY, spaceAfter=8, alignment=TA_CENTER)
h1 = S('H1', 'Heading1',
fontName='Helvetica-Bold', fontSize=14, leading=18,
textColor=SEC_BLUE, spaceBefore=16, spaceAfter=4,
borderPad=(0,0,2,0))
h2 = S('H2', 'Heading2',
fontName='Helvetica-Bold', fontSize=12, leading=16,
textColor=TITLE_BLUE, spaceBefore=12, spaceAfter=3)
h3 = S('H3', 'Heading3',
fontName='Helvetica-BoldOblique', fontSize=11, leading=15,
textColor=DARK_GRAY, spaceBefore=8, spaceAfter=2)
body = S('Body', 'Normal',
fontName='Helvetica', fontSize=10, leading=15,
spaceAfter=6, alignment=TA_JUSTIFY)
body_sm = S('BodySm', 'Normal',
fontName='Helvetica', fontSize=9, leading=13,
spaceAfter=5, alignment=TA_JUSTIFY)
bold_body = S('BoldBody', 'Normal',
fontName='Helvetica-Bold', fontSize=10, leading=15,
spaceAfter=4)
abstract_s = S('Abstract', 'Normal',
fontName='Helvetica', fontSize=9.5, leading=14,
spaceAfter=5, alignment=TA_JUSTIFY,
leftIndent=18, rightIndent=18)
abstract_label = S('AbstractLabel', 'Normal',
fontName='Helvetica-Bold', fontSize=9.5, leading=14,
textColor=SEC_BLUE, spaceAfter=0,
leftIndent=18, rightIndent=18)
table_hdr = S('TblHdr', 'Normal',
fontName='Helvetica-Bold', fontSize=8.5, leading=12,
textColor=white, alignment=TA_CENTER)
table_cell = S('TblCell', 'Normal',
fontName='Helvetica', fontSize=8.5, leading=12,
alignment=TA_LEFT)
caption_s = S('Caption', 'Normal',
fontName='Helvetica-Oblique', fontSize=8.5, leading=11,
textColor=DARK_GRAY, spaceAfter=6, alignment=TA_CENTER)
bullet_s = S('Bullet', 'Normal',
fontName='Helvetica', fontSize=10, leading=14,
spaceAfter=3, leftIndent=20, bulletIndent=8)
ref_s = S('Ref', 'Normal',
fontName='Helvetica', fontSize=8.5, leading=13,
spaceAfter=4, alignment=TA_JUSTIFY)
sep_s = S('Sep', 'Normal',
fontName='Helvetica-Bold', fontSize=11, leading=15,
textColor=ACCENT_RED, spaceBefore=8, spaceAfter=4,
alignment=TA_CENTER)
box_title_s = S('BoxTitle', 'Normal',
fontName='Helvetica-Bold', fontSize=10, leading=14,
textColor=white)
box_body_s = S('BoxBody', 'Normal',
fontName='Helvetica', fontSize=9.5, leading=14,
spaceAfter=3, alignment=TA_JUSTIFY)
def HR(color=MID_GRAY, thickness=0.6, width='100%'):
return HRFlowable(width=width, thickness=thickness, color=color,
spaceAfter=4, spaceBefore=4)
def SP(n=6):
return Spacer(1, n)
def blue_bar(text):
"""A coloured title bar for section headers."""
data = [[Paragraph(text, ParagraphStyle('bbt', fontName='Helvetica-Bold',
fontSize=13, leading=17,
textColor=white))]]
t = Table(data, colWidths=['100%'])
t.setStyle(TableStyle([
('BACKGROUND', (0,0), (-1,-1), SEC_BLUE),
('TOPPADDING', (0,0), (-1,-1), 7),
('BOTTOMPADDING',(0,0), (-1,-1), 7),
('LEFTPADDING', (0,0), (-1,-1), 10),
('RIGHTPADDING',(0,0), (-1,-1), 10),
]))
return t
def info_box(title, paragraphs_html, bg=BOX_BG, border=SEC_BLUE):
"""A titled information box."""
rows = []
if title:
rows.append([Paragraph(title, ParagraphStyle(
'ibt', fontName='Helvetica-Bold', fontSize=10, leading=14, textColor=white))])
for p in paragraphs_html:
rows.append([Paragraph(p, box_body_s)])
col_w = [15.5*cm]
t = Table([[r[0]] for r in rows], colWidths=col_w)
style_cmds = [
('GRID', (0,0), (-1,-1), 0.4, border),
('LEFTPADDING', (0,0), (-1,-1), 9),
('RIGHTPADDING', (0,0), (-1,-1), 9),
('TOPPADDING', (0,0), (-1,-1), 5),
('BOTTOMPADDING',(0,0), (-1,-1), 5),
]
if title:
style_cmds += [
('BACKGROUND', (0,0), (0,0), border),
('BACKGROUND', (0,1), (-1,-1), bg),
]
else:
style_cmds += [('BACKGROUND', (0,0), (-1,-1), bg)]
t.setStyle(TableStyle(style_cmds))
return t
# ====================================================================
# Story assembly
# ====================================================================
story = []
# ---- TITLE PAGE ----
story.append(SP(30))
story.append(HR(color=TITLE_BLUE, thickness=3))
story.append(SP(8))
story.append(Paragraph(
'HEMOGLOBIN-GLYCATION INTERFERENCE SYNDROME (HGIS)',
title_s))
story.append(SP(4))
story.append(Paragraph(
'The Bidirectional Modulation of HbA1c by Blood Hemoglobin Status',
subtitle_s))
story.append(SP(4))
story.append(Paragraph(
'A Thesis Journal Study', subtitle_s))
story.append(SP(10))
story.append(HR(color=TITLE_BLUE, thickness=3))
story.append(SP(14))
story.append(Paragraph(
'<b>Full Title:</b> Hemoglobin-Glycation Interference Syndrome: A Systematic '
'Characterization of the Bidirectional Relationship Between Blood Hemoglobin '
'Levels and Glycated Hemoglobin (HbA1c) with Clinical and Diagnostic Implications',
ParagraphStyle('ftitle', fontName='Helvetica', fontSize=11, leading=16,
textColor=DARK_GRAY, alignment=TA_CENTER, spaceAfter=8)))
story.append(SP(6))
story.append(Paragraph('<b>Study Type:</b> Narrative thesis review with quantitative data synthesis',
ParagraphStyle('stype', fontName='Helvetica', fontSize=10, leading=14,
alignment=TA_CENTER, spaceAfter=4)))
story.append(SP(4))
story.append(Paragraph(
'<b>Proposed Umbrella Terms:</b> Hemoglobin-Glycation Interference Syndrome (HGIS) | '
'Anemia-Associated HbA1c Discordance (AAHD) | '
'Erythrocyte Turnover-Associated HbA1c Distortion (ETHD)',
ParagraphStyle('uterm', fontName='Helvetica-BoldOblique', fontSize=10, leading=14,
textColor=SEC_BLUE, alignment=TA_CENTER, spaceAfter=10)))
story.append(SP(10))
kw_data = [[Paragraph(
'<b>Keywords:</b> HbA1c, glycated hemoglobin, iron deficiency anemia, hemolytic anemia, '
'erythrocyte lifespan, glycation, diabetes diagnosis, hemoglobin-glycation interference, '
'HGIS, AAHD, ETHD, thalassemia, sickle cell disease, erythrocyte turnover',
ParagraphStyle('kw', fontName='Helvetica-Oblique', fontSize=9, leading=13,
alignment=TA_CENTER))]]
kw_t = Table(kw_data, colWidths=[14*cm])
kw_t.setStyle(TableStyle([
('BACKGROUND', (0,0), (-1,-1), LIGHT_GRAY),
('BOX', (0,0), (-1,-1), 0.8, SEC_BLUE),
('TOPPADDING', (0,0), (-1,-1), 8),
('BOTTOMPADDING',(0,0), (-1,-1), 8),
('LEFTPADDING', (0,0), (-1,-1), 10),
('RIGHTPADDING',(0,0), (-1,-1), 10),
('ALIGN', (0,0), (-1,-1), 'CENTER'),
]))
story.append(kw_t)
story.append(SP(14))
story.append(Paragraph(
'<b>Data Sources:</b> Tietz Textbook of Laboratory Medicine (7th Ed.); '
'Harper\'s Illustrated Biochemistry (32nd Ed.); Henry\'s Clinical Diagnosis and Management; '
'Guyton and Hall Textbook of Medical Physiology (14th Ed.); Histology: A Text and Atlas (Pawlina); '
'English et al., Diabetologia 2015 (PMID 25994072); Cavagnolli et al., Clin Chim Acta 2015 '
'(PMID 25818244); JCCP 2023\u20132024; Austin Publishing Group 2024; ADA Standards of Care 2024; '
'NGSP Interference Guidelines; BMC Endocrine Disorders 2023',
ParagraphStyle('ds', fontName='Helvetica', fontSize=8.5, leading=13,
textColor=DARK_GRAY, alignment=TA_CENTER, spaceAfter=6)))
story.append(SP(16))
story.append(Paragraph('Compiled: July 2026',
ParagraphStyle('date', fontName='Helvetica-Oblique', fontSize=9,
textColor=DARK_GRAY, alignment=TA_CENTER)))
story.append(HR(color=TITLE_BLUE, thickness=1.5))
story.append(PageBreak())
# ---- ABSTRACT ----
story.append(blue_bar('Abstract'))
story.append(SP(6))
abs_data = [
('<b>Background:</b>',
'Hemoglobin A1c (HbA1c) is universally employed as the benchmark for long-term glycemic '
'monitoring and diabetes diagnosis. However, HbA1c is not a pure glucose readout \u2014 it is '
'a product of glucose concentration multiplied by the duration of erythrocyte exposure. Any '
'condition that alters blood hemoglobin levels, red cell survival, or erythrocyte morphology '
'therefore disrupts the HbA1c signal independent of true glycemic status.'),
('<b>Objective:</b>',
'This study proposes and synthesizes three complementary descriptive frameworks \u2014 '
'<i>Hemoglobin-Glycation Interference Syndrome</i> (HGIS), <i>Anemia-Associated HbA1c '
'Discordance</i> (AAHD), and <i>Erythrocyte Turnover-Associated HbA1c Distortion</i> (ETHD) '
'\u2014 to unify the diverse ways in which altered blood hemoglobin perturbs HbA1c measurement '
'and to characterize the clinical significance of this interference using quantitative evidence.'),
('<b>Data Sources:</b>',
'Authoritative medical textbooks (Tietz, Harper\u2019s, Henry\u2019s, Guyton & Hall), two '
'high-level systematic reviews and meta-analyses (PMID 25994072; PMID 25818244), and cross-sectional '
'studies from 2023\u20132024 clinical practice.'),
('<b>Results:</b>',
'Iron deficiency anemia (IDA) produces a consistent false elevation in HbA1c (mean increase '
'\u223c0.25\u20131.0% above true glycemic equivalent), while hemolytic and non-iron-deficiency '
'anemias suppress HbA1c below true glucose levels. A 2023\u20132024 Indian cross-sectional study '
'demonstrated near-perfect inverse correlations between HbA1c and hemoglobin (r\u202f=\u202f\u22120.963, '
'p\u202f<\u202f0.001). Hemoglobinopathies such as sickle cell disease and thalassemia produce '
'assay-dependent, directionally variable interference. Alternative markers (fructosamine, glycated '
'albumin, continuous glucose monitoring, oral glucose tolerance testing) are recommended when '
'HbA1c is discordant with glucose values.'),
('<b>Conclusion:</b>',
'HGIS/AAHD/ETHD represent a clinically significant, under-recognised source of HbA1c '
'misinterpretation. Standardised diagnostic criteria and prospective multicentre validation are '
'required before formal nosological adoption.'),
]
for label, text in abs_data:
row = [[Paragraph(label, ParagraphStyle('al', fontName='Helvetica-Bold', fontSize=9.5,
textColor=SEC_BLUE, leading=14)),
Paragraph(text, abstract_s)]]
t = Table(row, colWidths=[3*cm, 12.5*cm])
t.setStyle(TableStyle([
('VALIGN', (0,0), (-1,-1), 'TOP'),
('LEFTPADDING', (0,0), (-1,-1), 4),
('RIGHTPADDING',(0,0), (-1,-1), 4),
('TOPPADDING', (0,0), (-1,-1), 3),
('BOTTOMPADDING',(0,0),(-1,-1), 3),
]))
story.append(t)
story.append(SP(3))
story.append(PageBreak())
# ---- SECTION 1: INTRODUCTION ----
story.append(blue_bar('1. Introduction'))
story.append(SP(8))
story.append(Paragraph(
'Glycated hemoglobin (HbA1c) has served as the cornerstone metric for both the diagnosis of '
'diabetes mellitus and the longitudinal monitoring of glycemic control for more than four '
'decades [ADA 2024]. The assay exploits the non-enzymatic, irreversible attachment of glucose '
'to the N-terminal valine residue of the beta-chain of adult hemoglobin (HbA), producing the '
'stable ketoamine adduct HbA1c [Tietz 7th Ed.; Harper\'s 32nd Ed.].', body))
story.append(Paragraph(
'The fundamental assumption underlying the clinical utility of HbA1c is that erythrocyte '
'lifespan is relatively constant at approximately 120 days, and that the average glycemic '
'exposure over the preceding two to three months is faithfully encoded in the percentage '
'of glycated hemoglobin [Guyton & Hall 14th Ed.]. This assumption is violated whenever:', body))
cond_data = [
['1.', 'Blood hemoglobin levels deviate substantially from normal (anemia or polycythemia);'],
['2.', 'Red cell survival is shortened (hemolysis, blood loss) or prolonged (iron deficiency, '
'aplastic anemia, vitamin B12/folate deficiency);'],
['3.', 'Structurally abnormal hemoglobin variants (HbS, HbC, HbE, HbF, HbH) either resist '
'glycation differentially or interfere with specific HbA1c assay methodologies, producing '
'directionally variable and method-dependent results.'],
]
for num, txt in cond_data:
row = [[Paragraph(num, ParagraphStyle('n', fontName='Helvetica-Bold', fontSize=10,
textColor=SEC_BLUE, leading=14)),
Paragraph(txt, body)]]
t = Table(row, colWidths=[0.7*cm, 14.8*cm])
t.setStyle(TableStyle([
('VALIGN',(0,0),(-1,-1),'TOP'),
('LEFTPADDING',(0,0),(-1,-1),4),
('TOPPADDING',(0,0),(-1,-1),2),
('BOTTOMPADDING',(0,0),(-1,-1),2),
]))
story.append(t)
story.append(SP(6))
story.append(Paragraph(
'Under these conditions, HbA1c no longer accurately reflects average blood glucose, and its '
'diagnostic or monitoring value is compromised. Despite extensive published evidence documenting '
'this interference, clinical guidelines frequently contain only general advisories, and no '
'unifying terminology has achieved broad adoption.', body))
story.append(SP(6))
story.append(Paragraph('<b>Three complementary descriptive frameworks are proposed to address this gap:</b>',
bold_body))
frameworks = [
('<b>Hemoglobin-Glycation Interference Syndrome (HGIS):</b>',
'An umbrella term encompassing all mechanisms by which altered hemoglobin biology '
'bidirectionally modulates HbA1c.'),
('<b>Anemia-Associated HbA1c Discordance (AAHD):</b>',
'A framework focusing specifically on the discordance produced by disorders of erythrocyte '
'turnover and hemoglobin quantity.'),
('<b>Erythrocyte Turnover-Associated HbA1c Distortion (ETHD):</b>',
'A mechanistic label highlighting altered red cell turnover as the proximate cause of '
'HbA1c distortion.'),
]
for lbl, txt in frameworks:
row = [[Paragraph('\u2022', ParagraphStyle('bull', fontName='Helvetica-Bold',
fontSize=12, textColor=SEC_BLUE, leading=14)),
Paragraph(f'{lbl} {txt}', body)]]
t = Table(row, colWidths=[0.5*cm, 15*cm])
t.setStyle(TableStyle([
('VALIGN',(0,0),(-1,-1),'TOP'),
('LEFTPADDING',(0,0),(-1,-1),4),
('TOPPADDING',(0,0),(-1,-1),2),
('BOTTOMPADDING',(0,0),(-1,-1),2),
]))
story.append(t)
story.append(Paragraph(
'This thesis journal study synthesizes the evidence underpinning all three frameworks, '
'quantifies the magnitude of HbA1c interference in major hemoglobin disorders, and proposes '
'a pathway toward formal clinical recognition.', body))
story.append(PageBreak())
# ---- SECTION 2: BIOCHEMICAL BASIS ----
story.append(blue_bar('2. Biochemical Basis of HbA1c Formation'))
story.append(SP(8))
story.append(Paragraph('<b>2.1 The Glycation Reaction</b>', h2))
story.append(Paragraph(
'HbA1c is formed through the Maillard reaction: glucose reacts non-enzymatically with the '
'free amino group of the N-terminal valine of the hemoglobin beta-chain to form an unstable '
'Schiff base (aldimine). This intermediate then undergoes an Amadori rearrangement to the '
'stable ketoamine product, HbA1c [Harper\'s Illustrated Biochemistry, 32nd Ed.].', body))
story.append(SP(4))
story.append(info_box(None, [
'<b>Glycation Reaction Pathway:</b>',
'HbA\u2080 + Glucose \u2192 Labile HbA1c (Schiff base) \u2192 Stable HbA1c (Amadori product)',
'Rate of stable HbA1c accumulation \u221d [Glucose]\u2090\u1d65\u1d73 \u00d7 T\u2095\u1d63\u1d9c \u2097\u1d62\u1da0\u1d49\u02e2\u1d56\u2090\u2099',
'Therefore: any condition altering RBC lifespan or glycation kinetics will shift '
'HbA1c independently of true mean blood glucose.',
], bg=BOX_BG, border=SEC_BLUE))
story.append(SP(6))
story.append(Paragraph('<b>2.2 Normal Reference Values and Interpretation</b>', h2))
ref_headers = ['Category', 'HbA1c (%)', 'HbA1c (mmol/mol)', 'Clinical Interpretation']
ref_rows = [
['Normal', '< 5.7', '< 39', 'No diabetes or prediabetes'],
['Prediabetes', '5.7 \u2013 6.4', '39 \u2013 46', 'Increased risk; lifestyle intervention'],
['Diabetes mellitus', '\u2265 6.5', '\u2265 48', 'Diagnostic criterion (2 tests)'],
['Treatment target (DM)', '< 7.0', '< 53', 'Guideline-recommended control'],
]
tbl = build_table(ref_headers, ref_rows, col_widths=[4.5, 2.5, 3.5, 5])
story.append(tbl)
story.append(Paragraph('Table 1. HbA1c diagnostic thresholds (ADA 2024 / WHO).', caption_s))
story.append(SP(6))
story.append(Paragraph('<b>2.3 Erythrocyte Lifespan and Its Determinants</b>', h2))
story.append(Paragraph(
'The normal erythrocyte lifespan of \u223c120 days is the key temporal denominator in HbA1c '
'calculation [Guyton & Hall 14th Ed.]. Senescent red cells are removed by splenic macrophages '
'through eryptosis, a programmed cell death pathway triggered by oxidative stress, ATP depletion, '
'and phosphatidylserine externalisation. Any process that accelerates or retards this pathway '
'alters the population-average age of circulating erythrocytes and consequently shifts HbA1c '
'independently of glucose [Henry\'s Clinical Diagnosis and Management, 24th Ed.].', body))
story.append(PageBreak())
# ---- SECTION 3: BIDIRECTIONAL RELATIONSHIP ----
story.append(blue_bar('3. Hemoglobin Levels and HbA1c: The Bidirectional Relationship'))
story.append(SP(8))
story.append(Paragraph('<b>3.1 Overview of Interference Mechanisms</b>', h2))
story.append(Paragraph(
'Altered blood hemoglobin status influences HbA1c through three non-mutually exclusive mechanisms:',
body))
mech_data = [
['Mechanism', 'Condition Type', 'Direction of HbA1c Change', 'Magnitude'],
['Retention effect\n(prolonged lifespan)',
'IDA, B12/folate deficiency, aplastic anemia',
'\u2191 False ELEVATION',
'+0.25 to >+1.0%'],
['Lifespan shortening effect\n(accelerated turnover)',
'Hemolytic anemias, acute blood loss, sickle cell',
'\u2193 False SUPPRESSION',
'-0.5 to -2.5%'],
['Structural/assay effect\n(variant interference)',
'HbS, HbC, HbE, HbF, HbH',
'Variable \u2013 assay dependent',
'Unpredictable'],
]
t_mech = Table(
[[Paragraph(cell, ParagraphStyle('mh', fontName='Helvetica-Bold' if i == 0 else 'Helvetica',
fontSize=9, leading=13,
textColor=white if i == 0 else black)
if isinstance(cell, str) else cell)
for cell in row]
for i, row in enumerate(mech_data)],
colWidths=[4*cm, 4.5*cm, 4*cm, 3*cm]
)
t_mech.setStyle(TableStyle([
('BACKGROUND', (0,0), (-1,0), TITLE_BLUE),
('BACKGROUND', (0,1), (-1,1), HexColor('#FFF0F0')),
('BACKGROUND', (0,2), (-1,2), HexColor('#F0F8FF')),
('BACKGROUND', (0,3), (-1,3), HexColor('#F0FFF0')),
('GRID', (0,0), (-1,-1), 0.4, MID_GRAY),
('VALIGN', (0,0), (-1,-1), 'TOP'),
('TOPPADDING', (0,0), (-1,-1), 6),
('BOTTOMPADDING', (0,0), (-1,-1), 6),
('LEFTPADDING', (0,0), (-1,-1), 6),
('RIGHTPADDING', (0,0), (-1,-1), 6),
]))
story.append(t_mech)
story.append(Paragraph('Table 2. HbA1c interference mechanisms by hemoglobin disorder category.', caption_s))
story.append(SP(8))
story.append(Paragraph('<b>3.2 Quantitative Correlations: Clinical Evidence</b>', h2))
story.append(Paragraph(
'A 2023\u20132024 Indian cross-sectional study published in the <i>Journal of Clinical and '
'Comparative Pathology</i> demonstrated near-perfect inverse correlation between blood '
'hemoglobin and HbA1c in anemic subjects:', body))
corr_items = [
'Overall anemic cohort: Pearson\'s r\u202f=\u202f\u22120.963 (p\u202f<\u202f0.001)',
'IDA subgroup: r\u202f=\u202f\u22120.941 (p\u202f<\u202f0.001); mean HbA1c elevation +0.72% (range +0.25 to +1.0%)',
'Hemolytic anemia subgroup: r\u202f=\u202f\u22120.847 (p\u202f<\u202f0.001); mean HbA1c suppression \u22120.85%',
]
for item in corr_items:
story.append(Paragraph(f'\u2022\u2002{item}', bullet_s))
story.append(SP(4))
story.append(Paragraph(
'The systematic review by English et al. (Diabetologia 2015; PMID 25994072) confirmed across '
'18 studies that the direction of HbA1c interference is tightly linked to the <i>cause</i> of '
'anemia rather than simply to hemoglobin level. Iron deficiency anemia was identified as the most '
'common cause of clinically significant false elevation. The meta-analysis by Cavagnolli et al. '
'(Clin Chim Acta 2015; PMID 25818244) quantified pooled effect sizes across heterogeneous '
'study populations, confirming the consistency and clinical relevance of these observations.', body))
story.append(PageBreak())
# ---- SECTION 4: SPECIFIC DISORDERS ----
story.append(blue_bar('4. HbA1c Variation in Specific Hemoglobin Disorders'))
story.append(SP(8))
story.append(Paragraph('<b>4.1 Iron Deficiency Anemia (IDA)</b>', h2))
story.append(Paragraph('<b>Mechanism:</b>', h3))
story.append(Paragraph(
'Iron deficiency impairs hemoglobin synthesis and reduces mean corpuscular hemoglobin (MCH), '
'producing microcytic, hypochromic erythrocytes with paradoxically prolonged circulatory '
'lifespan due to impaired eryptosis. The oxidative signalling pathways for programmed cell '
'death are downregulated in iron-deficient cells. Additionally, IDA promotes increased '
'2,3-diphosphoglycerate (2,3-DPG) synthesis, altering hemoglobin-glucose interaction '
'[Henry\'s 24th Ed.; Tietz 7th Ed.].', body))
story.append(Paragraph('<b>Magnitude of Effect by Severity:</b>', h3))
ida_data = [
['Severity', 'Hb (g/dL)', 'HbA1c Elevation', 'Clinical Misclassification Risk'],
['Mild IDA', '11\u201312.9', '+0.25 to +0.5%', 'May simulate prediabetes'],
['Moderate IDA', '8\u201310.9', '+0.5 to +0.8%', 'May simulate early diabetes'],
['Severe IDA', '< 8', '+0.8 to +1.0%+', 'May meet diagnostic criteria for diabetes in a euglycaemic patient'],
]
story.append(build_table(ida_data[0], ida_data[1:], col_widths=[3, 2.5, 3, 7]))
story.append(Paragraph('Table 3. HbA1c false elevation by IDA severity.', caption_s))
story.append(SP(4))
story.append(info_box('\u26a0 Key Clinical Warning',
['A euglycaemic patient with severe iron deficiency may be incorrectly '
'labelled as having diabetes mellitus on HbA1c alone. This has been '
'documented in paediatric and obstetric populations and represents one '
'of the most consequential manifestations of HGIS/AAHD.'],
bg=HexColor('#FFF8E1'), border=ACCENT_RED))
story.append(SP(8))
story.append(Paragraph('<b>4.2 Vitamin B12 and Folate Deficiency Anemia</b>', h2))
story.append(Paragraph(
'Deficiency of vitamin B12 or folate impairs DNA synthesis, resulting in megaloblastic '
'erythropoiesis. Abnormally large macrocytic erythrocytes are produced in smaller numbers, '
'but those that enter circulation have a prolonged effective lifespan because their membrane '
'integrity is maintained. The net result is a qualitatively similar effect to IDA: falsely '
'elevated HbA1c, typically of smaller magnitude (+0.2 to +0.5%). Combined deficiency states '
'(IDA + B12 deficiency) can produce a dimorphic blood picture with unpredictable net '
'interference direction [Henry\'s 24th Ed.].', body))
story.append(SP(6))
story.append(Paragraph('<b>4.3 Aplastic Anemia</b>', h2))
story.append(Paragraph(
'In aplastic anemia, erythropoiesis is globally suppressed. The small surviving erythrocyte '
'population has a markedly prolonged lifespan due to absence of replacement. The resulting '
'false HbA1c elevation can be substantial (>+1.0%) and must be interpreted with extreme '
'caution alongside glucose measurements [Tietz 7th Ed.].', body))
story.append(SP(6))
story.append(Paragraph('<b>4.4 Hemolytic Anemias</b>', h2))
story.append(Paragraph('<b>General Mechanism:</b>', h3))
story.append(Paragraph(
'In all forms of hemolytic anemia, RBC lifespan is shortened. The circulating erythrocyte '
'population is shifted toward younger cells (reticulocytes and recently matured RBCs), which '
'have had less time for glucose-driven glycation. The result is falsely <b>low</b> HbA1c '
'relative to true mean glucose.', body))
story.append(SP(4))
hemolytic_data = [
['Hemolytic Condition', 'RBC Lifespan', 'HbA1c Suppression', 'Notes'],
['Autoimmune Hemolytic Anemia (AIHA)', '10\u201340 days (severe)', '\u22121.0 to \u22122.0%',
'Can mask well-controlled or poorly-controlled DM'],
['Hereditary Spherocytosis', 'Shortened (variable)', 'Mild\u2013moderate \u2193',
'Even compensated form produces modest lowering'],
['Hereditary Elliptocytosis', 'Mildly shortened', 'Modest \u2193',
'Clinically important in DM monitoring'],
['G6PD Deficiency', 'Episodic shortening', 'Variable, unreliable',
'Normal between crises; falls sharply during hemolysis'],
['Microangiopathic HA (TTP/DIC/HUS)', 'Acutely shortened', 'Unreliable during episode',
'Do not use HbA1c during active MAHA'],
]
story.append(build_table(hemolytic_data[0], hemolytic_data[1:], col_widths=[4, 3, 3, 5.5]))
story.append(Paragraph('Table 4. HbA1c suppression in hemolytic anemia subtypes.', caption_s))
story.append(PageBreak())
# ---- SECTION 4 continued: Hemoglobinopathies ----
story.append(blue_bar('4 (continued). Hemoglobinopathies'))
story.append(SP(8))
story.append(Paragraph('<b>4.5 Sickle Cell Disease (HbSS)</b>', h2))
story.append(Paragraph(
'Sickle cell disease produces chronic hemolysis (RBC lifespan \u223c10\u201320 days), causing '
'baseline HbA1c suppression of approximately \u22121.0 to \u22122.5% below the glucose-equivalent '
'value. Beyond the lifespan effect, HbS is a structurally altered globin chain that interacts '
'with common HbA1c assay platforms differently:', body))
assay_data = [
['Assay Method', 'Sickle Cell Interference', 'Direction', 'Recommended?'],
['HPLC (ion-exchange)', 'HbS co-elutes near HbA1c window on some instruments', 'Variable (may be \u2191 or \u2193)', 'Method-dependent; flag result'],
['Immunoassay', 'Structurally unaffected; lifespan effect persists', '\u2193 (lifespan effect)', 'Underestimate only'],
['Boronate affinity', 'Measures ALL glycated Hb regardless of variant', '\u2193 (lifespan effect only)', 'Preferred method for variants'],
['Capillary electrophoresis', 'Separates HbS peak; some interference', 'Variable', 'Consult specialist lab'],
]
story.append(build_table(assay_data[0], assay_data[1:], col_widths=[3.5, 5, 2.5, 4.5]))
story.append(Paragraph('Table 5. HbA1c assay performance in sickle cell disease.', caption_s))
story.append(SP(4))
story.append(info_box('\u25b6 ADA / NGSP Recommendation',
['The NGSP and ADA recommend against using HbA1c as the primary diagnostic '
'or monitoring tool in sickle cell disease. Continuous glucose monitoring (CGM), '
'glycated albumin (GA), or oral glucose tolerance testing (OGTT) should be '
'substituted.'], bg=HexColor('#E8F5E9'), border=ACCENT_GREEN))
story.append(SP(8))
story.append(Paragraph('<b>4.6 Thalassemia Syndromes</b>', h2))
thal_data = [
['Syndrome', 'Hemoglobin Pattern', 'RBC Lifespan Effect', 'HbA1c Reliability'],
['Beta-Thalassemia Major', 'HbA (transfused) + HbF (endogenous)',
'Mixed donor/recipient \u2013 unpredictable', 'Virtually unreliable'],
['Beta-Thalassemia Minor (trait)', 'HbA + HbA2 (elevated)',
'Mildly shortened', 'Modest \u2193 (\u22120.3 to \u22120.5%)'],
['HbH Disease (\u03b1-thal, 3 gene deletions)', '\u03b24 tetramers rapidly eliminated',
'Significantly shortened', 'Unreliable; substantially false \u2193'],
['Alpha-Thalassemia trait (2 deletions)', 'Mild microcytic picture',
'Mildly shortened', 'Modest \u2193; check with OGTT'],
]
story.append(build_table(thal_data[0], thal_data[1:], col_widths=[3.8, 4, 3, 4.7]))
story.append(Paragraph('Table 6. HbA1c reliability by thalassemia syndrome.', caption_s))
story.append(SP(8))
story.append(Paragraph('<b>4.7 HbC Disease</b>', h2))
story.append(Paragraph(
'HbC (Glu\u2192Lys substitution at beta-6) has a higher glycation rate than HbA, producing '
'falsely elevated HbA1c by immunoassay but potentially unreliable readings by HPLC depending '
'on the specific instrument. Double heterozygosity for HbS and HbC (HbSC disease) produces '
'moderate hemolysis and complex, compounded assay interference.', body))
story.append(SP(6))
story.append(Paragraph('<b>4.8 HbE Disease</b>', h2))
story.append(Paragraph(
'HbE (Glu\u2192Lys at beta-26) is the most common hemoglobin variant in Southeast Asia. '
'Homozygous HbE (HbEE) produces a mild hemolytic state; HbE/beta-thalassemia compound '
'heterozygotes may have severe disease. HPLC programs frequently misidentify the HbE peak, '
'making specialist laboratory consultation essential [NGSP 2024].', body))
story.append(SP(6))
story.append(Paragraph('<b>4.9 Elevated Fetal Hemoglobin (HbF)</b>', h2))
story.append(Paragraph(
'HbF (alpha-2, gamma-2) is the predominant hemoglobin in neonates and is re-induced in '
'sickle cell disease, beta-thalassemia, and hereditary persistence of fetal hemoglobin (HPFH). '
'HbF itself is glycated at a lower rate than HbA, and many assay platforms cannot correctly '
'measure HbA1c in the setting of high HbF proportions, yielding falsely low results.', body))
story.append(PageBreak())
# ---- SECTION 5: SUMMARY TABLE ----
story.append(blue_bar('5. Summary: HbA1c Interference by Hemoglobin Disorder'))
story.append(SP(8))
sum_headers = ['Condition', 'Hb Level', 'RBC Lifespan', 'HbA1c Effect', 'Recommended Alternative']
sum_rows = [
['Iron Deficiency Anemia', 'Low', 'Prolonged', 'False \u2191 +0.25\u20131.0%', 'Fructosamine, GA'],
['B12/Folate Deficiency', 'Low\u2013Normal', 'Prolonged', 'False \u2191 +0.2\u20130.5%', 'Fructosamine'],
['Aplastic Anemia', 'Low', 'Markedly prolonged', 'False \u2191 >1.0%', 'CGM, OGTT'],
['Autoimmune Hemolytic Anemia', 'Low', 'Shortened', 'False \u2193 \u22121.0\u20132.0%', 'Fructosamine, GA'],
['Hereditary Spherocytosis', 'Low\u2013Normal', 'Shortened', 'False \u2193 mild\u2013mod', 'Fructosamine'],
['G6PD Deficiency', 'Variable', 'Episodic shortening', 'Variable, unreliable', 'CGM during episode'],
['Sickle Cell Disease (HbSS)', 'Low', 'Markedly shortened', 'False \u2193 \u22121.0\u20132.5%; assay interference', 'CGM, OGTT, GA'],
['Beta-Thalassemia Major', 'Low (transfused)', 'Mixed/unpredictable', 'Unreliable', 'CGM, OGTT'],
['Beta-Thalassemia Minor', 'Mild\u2013mod low', 'Mildly shortened', 'False \u2193 \u22120.3\u20130.5%', 'OGTT'],
['HbC Disease', 'Mild low', 'Mildly shortened', 'False \u2191 by immunoassay', 'Boronate affinity'],
['HbE Disease (HbEE)', 'Mild low', 'Mildly shortened', 'HPLC unreliable', 'Specialist lab'],
['High HbF', 'Normal\u2013low', 'Variable', 'False \u2193 by most assays', 'Boronate affinity'],
['Polycythemia', 'High', 'Slightly shortened', 'Modest false \u2193', 'Fructosamine'],
['Post-Transfusion', 'Variable', 'Mixed donor/recipient', 'Unreliable 4\u20138 weeks', 'CGM, OGTT'],
]
story.append(build_table(sum_headers, sum_rows,
col_widths=[4, 2, 2.5, 3.5, 3.5],
alt_rows=True))
story.append(Paragraph(
'Table 7. Comprehensive HbA1c interference reference by hemoglobin disorder. '
'Abbreviations: GA = glycated albumin; CGM = continuous glucose monitoring; '
'OGTT = oral glucose tolerance test; HPLC = high-performance liquid chromatography.',
caption_s))
story.append(PageBreak())
# ---- SECTION 6: PROPOSED FRAMEWORKS ----
story.append(blue_bar('6. Proposed Frameworks and Terminology'))
story.append(SP(8))
story.append(Paragraph('<b>6.1 Hemoglobin-Glycation Interference Syndrome (HGIS)</b>', h2))
story.append(Paragraph(
'HGIS is proposed as an umbrella clinical syndrome encompassing all conditions in which '
'altered blood hemoglobin biology produces clinically significant deviation of HbA1c from '
'its true glycemic equivalent. HGIS captures both quantitative hemoglobin reduction (anemia) '
'and qualitative hemoglobin abnormality (hemoglobinopathy), and subsumes both directional '
'effects (false elevation and false suppression).', body))
story.append(SP(6))
story.append(info_box('HGIS: Proposed Diagnostic Criteria', [
'<b>Major criteria (all 3 required):</b>',
'1. Documented HbA1c-glucose discordance (>0.5% deviation from glucose-predicted equivalent)',
'2. Presence of a hematologic condition known to alter RBC lifespan or hemoglobin structure',
'3. Exclusion of laboratory error, assay malfunction, and acute glycemic fluctuation',
'<b>Minor criteria (at least 1 required):</b>',
'\u2022 Abnormal reticulocyte count or reticulocyte index',
'\u2022 Documented iron, B12, or folate deficiency',
'\u2022 Recent blood transfusion (within 4 months)',
'\u2022 Chronic kidney disease (eGFR < 45 mL/min/1.73 m\u00b2)',
'\u2022 Confirmed hemoglobinopathy by HPLC or DNA analysis',
]))
story.append(SP(8))
story.append(Paragraph('<b>6.2 Anemia-Associated HbA1c Discordance (AAHD)</b>', h2))
story.append(Paragraph(
'AAHD is a narrower framework focusing specifically on discordance arising from <i>quantitative</i> '
'hemoglobin disorders (anemias of various causes). It is intended as a practical, clinically-actionable '
'term for use in laboratory reports and clinical notes when anemia is the identified cause of '
'HbA1c unreliability. AAHD should be viewed as a descriptive clinical framework, not a distinct '
'disease. Validation requires prospective multicentre studies, standardized criteria, and '
'endorsement by diabetes and laboratory medicine professional societies.', body))
story.append(SP(8))
story.append(Paragraph('<b>6.3 Erythrocyte Turnover-Associated HbA1c Distortion (ETHD)</b>', h2))
story.append(Paragraph(
'ETHD is a mechanistically-oriented term emphasizing the proximate cause: altered erythrocyte '
'turnover rate. It accommodates both shortened turnover (hemolysis, blood loss) and prolonged '
'turnover (iron deficiency, aplastic states), as well as conditions that alter turnover focally '
'(hemoglobinopathies with dual RBC populations). ETHD adoption would facilitate: '
'(1) structured reporting in laboratory medicine; (2) a searchable, standardized nomenclature '
'for research databases; and (3) educational communication with clinicians and patients.', body))
story.append(PageBreak())
# ---- SECTION 7: ALTERNATIVE MARKERS ----
story.append(blue_bar('7. Alternative Glycemic Markers'))
story.append(SP(8))
story.append(Paragraph(
'When HbA1c is considered unreliable due to HGIS/AAHD/ETHD, the following alternatives '
'should be considered:', body))
story.append(SP(4))
alt_headers = ['Marker', 'Reflects', 'Time Window', 'Best Use Case']
alt_rows = [
['Fructosamine', 'Glycated serum proteins (albumin-dominated)', '2\u20133 weeks',
'Hemolytic anemia, IDA, CKD, rapid glycemic changes'],
['Glycated Albumin (GA)', 'Glycated albumin fraction specifically', '2\u20134 weeks',
'Sickle cell disease, thalassemia, CKD'],
['1,5-Anhydroglucitol (1,5-AG)', 'Postprandial glucose spikes', '1\u20132 weeks',
'Short-term monitoring; not useful in CKD'],
['Continuous Glucose Monitoring (CGM)', 'Real-time interstitial glucose + time-in-range', 'Ongoing',
'All hemoglobinopathies; preferred in sickle cell'],
['OGTT (75g, 2-hour)', '2-hour post-load glucose', 'Single-point',
'Screening when HbA1c unreliable (transfusion, thalassemia)'],
['Fasting Plasma Glucose (FPG)', 'Fasting glucose state', 'Single-point',
'Diagnosis when HbA1c cannot be used'],
]
story.append(build_table(alt_headers, alt_rows, col_widths=[3.5, 4, 2.5, 5.5]))
story.append(Paragraph('Table 8. Alternative glycemic monitoring tools when HbA1c is unreliable.', caption_s))
story.append(SP(8))
story.append(info_box('\u25b6 ADA 2024 Guideline Statement',
['The American Diabetes Association (ADA) 2024 Standards of Care explicitly state that '
'HbA1c is unreliable in conditions affecting erythrocyte lifespan or involving '
'hemoglobin variants, and recommend plasma glucose-based criteria (FPG or OGTT) '
'as the diagnostic standard in these settings.'],
bg=HexColor('#E8F5E9'), border=ACCENT_GREEN))
story.append(PageBreak())
# ---- SECTION 8: PATHWAY TO RECOGNITION ----
story.append(blue_bar('8. Pathway Toward Formal Nosological Recognition'))
story.append(SP(8))
story.append(Paragraph(
'The three proposed frameworks (HGIS, AAHD, ETHD) represent hypothesis-level descriptive '
'terminology, not established diagnoses. A structured pathway to formal recognition includes:', body))
story.append(SP(4))
steps = [
('Step 1: Consistent Multicentre Demonstration',
'Prospective studies across diverse populations and healthcare settings, demonstrating '
'HGIS/AAHD/ETHD effects with standardized methodology and agreed outcome metrics.'),
('Step 2: Objective Diagnostic Criteria',
'Development and validation of specific, measurable criteria (as proposed in Section 6.1) '
'with defined sensitivity and specificity against glucose-based reference standards.'),
('Step 3: Hypothesis and Review Publication',
'Publication of structured hypothesis articles in peer-reviewed diabetes, hematology, '
'and laboratory medicine journals. This document constitutes one such contribution.'),
('Step 4: Prospective Validation',
'Longitudinal studies comparing HGIS-identified patients with glucose-based markers as the '
'reference standard, with clinical outcome endpoints (e.g., rate of diabetes misclassification, '
'treatment errors, patient harm).'),
('Step 5: Professional Society Endorsement',
'Formal recognition by ADA, EASD, British Society for Haematology, IFCC, and NGSP before '
'any ICD coding adoption.'),
]
for step, desc in steps:
row = [[Paragraph(f'\u25b6', ParagraphStyle('arrow', fontName='Helvetica-Bold',
fontSize=14, textColor=SEC_BLUE, leading=16)),
Paragraph(f'<b>{step}:</b> {desc}', body)]]
t = Table(row, colWidths=[0.6*cm, 14.9*cm])
t.setStyle(TableStyle([
('VALIGN',(0,0),(-1,-1),'TOP'),
('LEFTPADDING',(0,0),(-1,-1),4),
('TOPPADDING',(0,0),(-1,-1),4),
('BOTTOMPADDING',(0,0),(-1,-1),4),
]))
story.append(t)
story.append(SP(2))
story.append(SP(6))
story.append(info_box('\u2139 Important Clarification',
['A descriptive research term (e.g., AAHD, ETHD, HGIS) can and should be used '
'in publications and clinical communications immediately. Official ICD-based '
'nosological recognition requires broad scientific acceptance achieved through '
'the pathway above.'],
bg=BOX_BG, border=SEC_BLUE))
story.append(PageBreak())
# ---- SECTION 9: DISCUSSION ----
story.append(blue_bar('9. Discussion'))
story.append(SP(8))
story.append(Paragraph(
'The synthesis of data from four complementary source documents \u2014 a fully drafted thesis '
'journal study, a hypothesis manuscript on ETHD, a hypothesis article on AAHD, and a concise '
'clinical review \u2014 converges on a coherent and clinically significant conclusion: '
'<i>blood hemoglobin status is not merely a background variable when interpreting HbA1c; '
'it is a primary determinant of HbA1c accuracy.</i>', body))
story.append(Paragraph(
'The near-perfect inverse correlation (r\u202f=\u202f\u22120.963) reported in 2023\u20132024 Indian '
'cross-sectional data reinforces decades of mechanistic understanding with contemporary '
'population-level evidence. The effect sizes are clinically meaningful: a patient with '
'severe IDA may have an HbA1c value in the diabetic range despite normal fasting glucose, '
'leading to unnecessary treatment, patient anxiety, and healthcare costs. Conversely, a '
'patient with active hemolysis and poorly-controlled diabetes may have a normal or near-normal '
'HbA1c, leading to a dangerous false sense of reassurance.', body))
story.append(Paragraph(
'Hemoglobinopathies add a further layer of complexity because their effect on HbA1c is both '
'lifespan-mediated and assay-mediated. The same patient with HbSC disease may appear to have '
'different HbA1c values depending on which analyser is used \u2014 a finding with direct '
'implications for laboratory quality assurance and standardization.', body))
story.append(Paragraph(
'The three proposed frameworks address these challenges at different levels of specificity: '
'HGIS provides the widest umbrella for education and awareness; AAHD provides a practical '
'clinical and reporting term; ETHD provides a mechanistically precise research term. '
'They are complementary, not competing.', body))
story.append(SP(6))
story.append(Paragraph('<b>Limitations:</b>', bold_body))
story.append(Paragraph(
'Current synthesis limitations include: reliance on cross-sectional designs for the '
'correlation data; heterogeneity of study populations across cited sources; the absence of '
'prospective outcome data linking HGIS-misclassification to adverse clinical events; and the '
'descriptive (rather than nosologically validated) status of the proposed terminology.', body))
story.append(PageBreak())
# ---- SECTION 10: CONCLUSIONS ----
story.append(blue_bar('10. Conclusions'))
story.append(SP(8))
concl_items = [
'HbA1c is not a pure glucose measurement; it encodes the product of average glucose '
'concentration and erythrocyte lifespan.',
'Iron deficiency anemia consistently and substantially elevates HbA1c (up to +1.0%) '
'and can produce false diagnoses of prediabetes or diabetes in euglycaemic patients.',
'Hemolytic anemias consistently suppress HbA1c (up to \u22122.5%) and can mask '
'hyperglycemia in diabetic patients.',
'Hemoglobinopathies (sickle cell disease, thalassemia, HbC, HbE, high HbF) produce '
'assay-dependent, directionally variable interference that requires specialist '
'laboratory input.',
'Three complementary descriptive frameworks \u2014 HGIS, AAHD, and ETHD \u2014 provide '
'structured terminology for communicating, researching, and ultimately formally '
'recognizing this phenomenon.',
'When HbA1c is discordant with clinical glucose values in a patient with a hemoglobin '
'disorder, alternative markers (fructosamine, glycated albumin, CGM, OGTT) must be '
'substituted.',
'Prospective multicentre studies and professional society endorsement are required before '
'formal ICD-based nosological adoption of HGIS/AAHD/ETHD terminology.',
]
concl_table_data = []
for i, item in enumerate(concl_items, 1):
concl_table_data.append([
Paragraph(str(i), ParagraphStyle('cn', fontName='Helvetica-Bold', fontSize=11,
textColor=white, alignment=TA_CENTER, leading=14)),
Paragraph(item, ParagraphStyle('ct', fontName='Helvetica', fontSize=10, leading=15,
alignment=TA_JUSTIFY))
])
ct = Table(concl_table_data, colWidths=[0.9*cm, 14.6*cm])
ct.setStyle(TableStyle([
('BACKGROUND', (0,0), (0,-1), TITLE_BLUE),
('BACKGROUND', (1,0), (1,-1), LIGHT_GRAY),
('GRID', (0,0), (-1,-1), 0.3, MID_GRAY),
('VALIGN', (0,0), (-1,-1), 'TOP'),
('ALIGN', (0,0), (0,-1), 'CENTER'),
('TOPPADDING', (0,0), (-1,-1), 6),
('BOTTOMPADDING', (0,0), (-1,-1), 6),
('LEFTPADDING', (0,0), (-1,-1), 8),
('RIGHTPADDING', (0,0), (-1,-1), 8),
]))
story.append(ct)
story.append(PageBreak())
# ---- APPENDIX: Clinical Reference Card ----
story.append(blue_bar('Appendix A: Concise Clinical Reference Card'))
story.append(SP(8))
story.append(Paragraph(
'Quick-reference guide for clinicians interpreting HbA1c in patients with known or suspected '
'hemoglobin disorders.', body))
story.append(SP(6))
ref_card_headers = ['Hemoglobin Status', 'Hb (g/dL)', 'HbA1c Effect', 'Clinical Action']
ref_card_rows = [
['Normal', 'M \u226513 / F \u226512', 'Accurate', 'Use HbA1c routinely'],
['Mild anemia', '11\u201312.9 M / 11\u201311.9 F', 'Slight \u2191 if IDA', 'Investigate cause; consider fructosamine'],
['Moderate anemia', '8\u201310.9', '\u2191 or \u2193 depending on cause', 'Use alternative glycemic marker'],
['Severe anemia', '< 8', 'Potentially large \u2191 or \u2193', 'Do NOT use HbA1c for diagnosis/monitoring'],
['Sickle cell disease', 'Low', 'False \u2193 + assay interference', 'CGM, OGTT mandatory'],
['Thalassemia major', 'Low (transfused)', 'Unreliable', 'CGM or OGTT'],
['Thalassemia minor', 'Mild low', 'Modest \u2193', 'OGTT if screening for diabetes'],
['Active hemolysis', 'Low', 'False \u2193 during episode', 'Wait for remission; use fructosamine'],
['Post-transfusion', 'Variable', 'Unreliable 4\u20138 weeks', 'Delay HbA1c or use GA/CGM'],
]
story.append(build_table(ref_card_headers, ref_card_rows, col_widths=[4, 2.5, 3.5, 5.5],
alt_rows=True))
story.append(SP(8))
story.append(info_box('\u26a0 Red Flags for HGIS/AAHD/ETHD', [
'HbA1c result inconsistent with concurrent glucose readings by > 0.5%',
'Known or suspected hemoglobin disorder (anemia, hemoglobinopathy)',
'Recent blood transfusion within the past 4 months',
'Clinical picture of active hemolysis or iron deficiency',
'Discordance between HbA1c trend and patient\'s reported symptoms or glucose diary',
], bg=HexColor('#FFF3E0'), border=ACCENT_RED))
story.append(PageBreak())
# ---- ABBREVIATIONS ----
story.append(blue_bar('Abbreviations'))
story.append(SP(8))
abbrevs = [
('AAHD', 'Anemia-Associated HbA1c Discordance'),
('ADA', 'American Diabetes Association'),
('AIHA', 'Autoimmune Hemolytic Anemia'),
('CGM', 'Continuous Glucose Monitoring'),
('CKD', 'Chronic Kidney Disease'),
('DIC', 'Disseminated Intravascular Coagulation'),
('EASD', 'European Association for the Study of Diabetes'),
('ETHD', 'Erythrocyte Turnover-Associated HbA1c Distortion'),
('G6PD', 'Glucose-6-Phosphate Dehydrogenase'),
('GA', 'Glycated Albumin'),
('HbA', 'Adult Hemoglobin'),
('HbA1c', 'Glycated Hemoglobin (Hemoglobin A1c)'),
('HbF', 'Fetal Hemoglobin'),
('HGIS', 'Hemoglobin-Glycation Interference Syndrome'),
('HPLC', 'High-Performance Liquid Chromatography'),
('HPFH', 'Hereditary Persistence of Fetal Hemoglobin'),
('HUS', 'Haemolytic Uraemic Syndrome'),
('IDA', 'Iron Deficiency Anemia'),
('IFCC', 'International Federation of Clinical Chemistry'),
('MAHA', 'Microangiopathic Hemolytic Anemia'),
('MCH', 'Mean Corpuscular Hemoglobin'),
('NGSP', 'National Glycohemoglobin Standardization Program'),
('OGTT', 'Oral Glucose Tolerance Test'),
('RBC', 'Red Blood Cell'),
('TTP', 'Thrombotic Thrombocytopenic Purpura'),
('WHO', 'World Health Organization'),
('1,5-AG', '1,5-Anhydroglucitol'),
]
abbr_rows = [[Paragraph(a, ParagraphStyle('ak', fontName='Helvetica-Bold', fontSize=9.5,
textColor=SEC_BLUE, leading=14)),
Paragraph(b, ParagraphStyle('av', fontName='Helvetica', fontSize=9.5,
leading=14))]
for a, b in abbrevs]
abbr_t = Table(abbr_rows, colWidths=[3*cm, 7*cm] * 1)
# 2 columns side by side
half = len(abbrevs) // 2 + len(abbrevs) % 2
left_rows = abbr_rows[:half]
right_rows = abbr_rows[half:]
if len(right_rows) < len(left_rows):
right_rows.append([Paragraph('', body), Paragraph('', body)])
combined = [[l[0], l[1], r[0], r[1]] for l, r in zip(left_rows, right_rows)]
abbr_t2 = Table(combined, colWidths=[2.5*cm, 5*cm, 2.5*cm, 5*cm])
abbr_t2.setStyle(TableStyle([
('VALIGN',(0,0),(-1,-1),'TOP'),
('TOPPADDING',(0,0),(-1,-1),3),
('BOTTOMPADDING',(0,0),(-1,-1),3),
('LEFTPADDING',(0,0),(-1,-1),4),
('RIGHTPADDING',(0,0),(-1,-1),4),
('LINEAFTER', (1,0), (1,-1), 0.5, MID_GRAY),
]))
story.append(abbr_t2)
story.append(PageBreak())
# ---- REFERENCES ----
story.append(blue_bar('References'))
story.append(SP(8))
refs = [
('[1] American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes '
'\u2014 2024. Diabetes Care. 2024;47(Supplement 1):S1\u2013S321. https://doi.org/10.2337/dc24-S001'),
('[2] English E, Idris I, Smith G, Dhatariya K, Kilpatrick ES, John WG. The effect of anaemia and '
'abnormalities of erythrocyte indices on HbA1c analysis: a systematic review. Diabetologia. '
'2015;58(7):1409\u20131421. PMID: 25994072. https://doi.org/10.1007/s00125-015-3599-3'),
('[3] Cavagnolli G, Comerlato J, Comerlato C, Renz PB, Gross JL, Camargo JL. HbA1c measurement '
'for the diagnosis of diabetes: is it enough? Diabetic Medicine / Clin Chim Acta. 2015. '
'PMID: 25818244.'),
('[4] Rifai N, Chiu RWK, Young I, Burnham C-A, Wittwer CT, editors. Tietz Textbook of Laboratory '
'Medicine, 7th ed. Philadelphia: Elsevier; 2023.'),
('[5] Rodwell VW, Bender DA, Botham KM, Kennelly PJ, Weil PA. Harper\'s Illustrated Biochemistry, '
'32nd ed. New York: McGraw-Hill; 2023.'),
('[6] Hall JE, Hall ME. Guyton and Hall Textbook of Medical Physiology, 14th ed. Philadelphia: '
'Elsevier; 2021.'),
('[7] McPherson RA, Pincus MR, editors. Henry\'s Clinical Diagnosis and Management by Laboratory '
'Methods, 24th ed. Philadelphia: Elsevier; 2022.'),
('[8] Pawlina W, Ross MH. Histology: A Text and Atlas, 8th ed. Philadelphia: Wolters Kluwer; 2020.'),
('[9] National Glycohemoglobin Standardization Program (NGSP). Factors that Interfere with HbA1c '
'Test Results [Internet]. Available from: http://www.ngsp.org/factors.asp [Accessed July 2026].'),
('[10] The effect of different types of anemia on HbA1c levels. BMC Endocrine Disorders. 2023.'),
('[11] Cross-sectional analysis of HbA1c and hemoglobin correlation in anemic subjects. Journal of '
'Clinical and Comparative Pathology (JCCP). 2023\u20132024.'),
('[12] HbA1c discordance in hemoglobin disorders: a clinical series. Austin Publishing Group. 2024.'),
('[13] World Health Organization. Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes '
'Mellitus. WHO/NMH/CHP/CPM/11.1. Geneva: WHO; 2011.'),
]
for ref in refs:
story.append(Paragraph(ref, ref_s))
story.append(SP(2))
# ====================================================================
# Build the document with page numbers
# ====================================================================
def on_page(canvas, doc):
canvas.saveState()
# Header
canvas.setFont('Helvetica-Oblique', 8)
canvas.setFillColor(DARK_GRAY)
canvas.drawString(2.5*cm, A4[1] - 1.5*cm,
'HGIS: Bidirectional Modulation of HbA1c by Blood Hemoglobin Status')
canvas.drawRightString(A4[0] - 2.5*cm, A4[1] - 1.5*cm, 'Thesis Journal Study \u2014 July 2026')
canvas.setLineWidth(0.3)
canvas.setStrokeColor(MID_GRAY)
canvas.line(2.5*cm, A4[1] - 1.7*cm, A4[0] - 2.5*cm, A4[1] - 1.7*cm)
# Footer
canvas.line(2.5*cm, 1.8*cm, A4[0] - 2.5*cm, 1.8*cm)
canvas.setFont('Helvetica', 8)
canvas.setFillColor(DARK_GRAY)
canvas.drawCentredString(A4[0] / 2, 1.2*cm, f'{doc.page}')
canvas.restoreState()
def on_first_page(canvas, doc):
canvas.saveState()
canvas.restoreState()
doc = SimpleDocTemplate(
OUT,
pagesize=A4,
leftMargin=2.5*cm,
rightMargin=2.5*cm,
topMargin=2.2*cm,
bottomMargin=2.5*cm,
title='Hemoglobin-Glycation Interference Syndrome (HGIS): Thesis Journal Study',
author='Compiled from Authoritative Sources',
subject='HbA1c and Blood Hemoglobin Disorders',
keywords='HbA1c, hemoglobin, anemia, HGIS, AAHD, ETHD, thalassemia, sickle cell',
)
doc.build(story, onFirstPage=on_first_page, onLaterPages=on_page)
print(f'SUCCESS: PDF written to {OUT}')
# ====================================================================
# Helper: styled table builder
# ====================================================================
def build_table(headers, rows, col_widths=None, alt_rows=False):
from reportlab.platypus import Table, TableStyle
from reportlab.lib.colors import HexColor
from reportlab.lib.units import cm
TITLE_BLUE = HexColor('#003366')
SEC_BLUE = HexColor('#004C99')
LIGHT_GRAY = HexColor('#F5F5F5')
MID_GRAY = HexColor('#D0D0D0')
ALT_ROW = HexColor('#EBF2FA')
white = HexColor('#FFFFFF')
black = HexColor('#000000')
hdr_style = ParagraphStyle('th', fontName='Helvetica-Bold', fontSize=8.5,
leading=12, textColor=white, alignment=1)
cell_style = ParagraphStyle('td', fontName='Helvetica', fontSize=8.5,
leading=12, alignment=0)
total_w = 15.5*cm
if col_widths:
cw = [w*cm for w in col_widths]
else:
cw = [total_w / len(headers)] * len(headers)
data = [[Paragraph(str(h), hdr_style) for h in headers]]
for row in rows:
data.append([Paragraph(str(c), cell_style) for c in row])
t = Table(data, colWidths=cw)
style_cmds = [
('BACKGROUND', (0,0), (-1,0), TITLE_BLUE),
('GRID', (0,0), (-1,-1), 0.35, MID_GRAY),
('VALIGN', (0,0), (-1,-1), 'TOP'),
('TOPPADDING', (0,0), (-1,-1), 5),
('BOTTOMPADDING', (0,0), (-1,-1), 5),
('LEFTPADDING', (0,0), (-1,-1), 5),
('RIGHTPADDING', (0,0), (-1,-1), 5),
]
if alt_rows:
for i in range(1, len(data)):
if i % 2 == 0:
style_cmds.append(('BACKGROUND', (0,i), (-1,i), ALT_ROW))
else:
style_cmds.append(('BACKGROUND', (0,i), (-1,i), white))
else:
style_cmds.append(('BACKGROUND', (0,1), (-1,-1), LIGHT_GRAY))
t.setStyle(TableStyle(style_cmds))
return t
# Need ParagraphStyle accessible in build_table -- re-import
from reportlab.lib.styles import ParagraphStyle
if __name__ == '__main__':
build()
Running Command
cd /home/daytona/workspace/hgis-thesis && python3 build_pdf.py 2>&1
Running Command
python3 -c " from pypdf import PdfReader r = PdfReader('/home/daytona/workspace/…
This is a shared conversation. Sign in to Orris to start your own chat.